元胡止痛片治疗溃疡型胃痛的物效机制
|
摘要
目的：
研究元胡止痛片治疗溃疡型胃痛的物效机制。
方法：
从细胞和整体动物水平，采用MTT、组织病理学、比色法检测、酶联免疫吸附测定、计算机辅助药物设计、RT-PCR以及多巴胺受体阻断剂等多种方法深入探讨元胡止痛片（母方）和延胡索乙素、欧前胡素及其延胡索乙素+欧前胡素（成分组方）治疗溃疡型胃痛的物效机制。
结果：
①母方及其成分组方可促进胃黏膜细胞增殖。组织病理学证实母方和成分组方能够有效促进乙酸致雄性SD大鼠胃黏膜损伤愈合。在体外，与模型组比较，3μg/ml延胡索乙素可促进GES-l细胞增殖14.7%(P<0.05)；2.4×10~(-1)μg/ml欧前胡素促进GES-l细胞增殖12.4%(P<0.05)；100μg/ml母方促进GES-l细胞增殖52.1%(P<0.05)。与8%乙醇损伤1h的GES-1模型组比较，3μg/ml延胡索乙素促进GES-l增殖26.5%(P<0.05)，2.4μg/ml欧前胡素促进GES-l增殖26.9%(P<0.05)，100μg/ml母方促进GES-l增殖27.1%(P<0.05)。在体内，对于乙酸致雄性SD大鼠胃溃疡的作用，与模型组相比，PCNA在以下各组中分别增加，50mg/kg延胡索乙素+40mg/kg欧前胡素组（组方I；151.2%；P<0.05），50mg/kg延胡索乙素+20mg/kg欧前胡素组（组方II组；144.6%；P<0.05），母方组（141.9%；P<0.05）。与50mg/kg延胡索乙素和40mg/kg欧前胡素组比较，组方I组分别上调447.8%(P<0.05)和298.7%(P<0.05)。②母方及其成分组方上调多种防御因素保护胃黏膜。对于乙酸致雄性SD大鼠胃溃疡，与模型组相比，SP在以下几组显著性上升，组方I（58.6%；P<0.01），组方II（40.4%；P<0.01），母方（41.8%；P<0.01)。与模型组相比，bFGF在以下处理组中增加，组方I(146.6%；P<0.01)，组方II(59.0%；P<0.05)和母方(182.8%；P<0.01)。与延胡索乙素或者欧前胡素单用相比或者与组方II相比，组方I均能显著提高bFGF含量(P<0.05)。这与以上组织病理学和抑制胃酸的结果一致。母方和成分组方能够减轻无水乙醇致雄性SD大鼠胃黏膜损伤。这与其清除自由基、维护ATPase、提高NOS以及EGF的作用机制相关。与模型组相比，母方提高总SOD含量125%(P<0.001)，组方I提高127.6%(P<0.001)，组方II提高97.0%(P<0.001)。延胡索乙素或欧前胡素分别单独使用，不能达到母方和成分组方的效果。并且与50mg/kg延胡索乙素，20mg/kg欧前胡素相比，组方I提高总SOD60.6%(P<0.05)和70.3%(P<0.05)。与模型组相比，母方降低MDA46.7%(P<0.05)，组方I降低MDA到51.6%(P<0.05)；组方II，延胡索乙素或欧前胡素分别单独使用，均不能显著性降低MDA。与模型组相比，母方提高Na+K+-ATPase43.2%(P<0.05)，组方I提高52.1%(P<0.05)。与50mg/kg延胡索乙素相比，组方I提高Na+K+-ATPase38.1%(P<0.05)。组方II，延胡索乙素或欧前胡素分别单独使用，均不能显著性提高Na+K+-ATPase。与模型组相比，母方提高Ca~(2+)Mg~(2+)-ATPase47.8%(P<0.05)，组方I提高58.0%(P<0.001)。与50mg/kg延胡索乙素相比，组方I提高Ca~(2+)Mg~(2+)-ATPase37.5%(P<0.05)。组方II，延胡索乙素或欧前胡素分别单独使用，均不能显著性提高Ca~(2+)Mg~(2+)ATPase。与模型组相比，TNOS在以下各组显著性提高：母方(105.5%, P<0.05)，组方I(149.2%, P<0.05)和组方II(94.5%，P<0.05)。延胡索乙素或欧前胡素分别单独使用，均不能显著性上调TNOS。与模型组相比，iNOS在以下用药组显著性提高：母方(115.6%, P<0.01)，组方I(120.9%, P<0.01)和组方II(63.4%，P<0.05)。延胡索乙素或欧前胡素分别单独使用，均不能显著性上调iNOS。与模型组相比，EGF在以下用药组显著性提高：母方(13.7%, P<0.05)，组方I(19.8%, P<0.01)。组方II，延胡索乙素或欧前胡素分别单独使用，均不能显著上调EGF。与模型组相比，TNF-α在以下用药组显著性提高：母方(39.6%, P<0.001)，组方I(44.9%, P<0.01)，组方II(85.3%, P<0.001)，50mg/kg延胡索乙素组(30.6%,P<0.05)，20mg/kg欧前胡素组(36.3%, P<0.05)。与组方I相比，组方II提高TNF-α含量27.9%(P<0.05)。③成分组方促进胃溃疡粘膜愈合与其上调乙酰胆碱酯酶活力、下调乙酰胆碱、降低H~+-K~+ATPase和抑制胃酸有关。对于乙酸致雄性SD大鼠胃溃疡，与模型组相比，组方I升高pH27.0%(P<0.05)，降低H~+-K~+ATPase活力47.9%(P<0.01)，上调乙酰胆碱酯酶活力90.4%(P<0.01)，下调乙酰胆碱37.2%(P<0.05)。其他给药处理组不能达到组方I的这些作用。④成分组方抑制胃黏膜损伤作用可被多潘立酮阻断。与无水乙醇致大鼠胃粘膜损伤模型组相比，组方I+0.2ml/只多潘立酮组的总SOD、MDA、Na+K+-ATPase、Ca~(2+)Mg~(2+)-ATPase均无显著性差异；但不干扰组方I对TNOS、iNOS、TNF-α的作用。0.2ml/只多潘立酮未干扰母方的以上作用机制（总SOD、MDA、Na+K+-ATPase、Ca~(2+)Mg~(2+)-ATPase、TNOS、iNOS、TNF-α）。0.2ml/只多潘立酮未干扰成分组方和母方对EGF的上调作用。与模型组相比，PGE2在以下用药组显著性下降：0.2ml/只多潘立酮组（45.4%，P<0.001），母方（28.4%，P<0.05），组方I+0.2ml/只多潘立酮（53.2%，P<0.001）。
结论：
①发现成分组方可显著促进乙酸所致大鼠胃溃疡损伤的愈合，减轻乙醇诱发的应激性伤害。该效果与元胡止痛片相一致；而且单独使用延胡索乙素或欧前胡素不能达到成分组方的效果。②首次揭示延胡索乙素和欧前胡素极有可能是元胡止痛片治疗溃疡型胃痛的物效成分。其理由，一是源自元胡止痛片的延胡索中延胡索乙素和白芷中欧前胡素，合并组成“成分组方”时具有协同起效的作用，并非化学物质药理作用的简单叠加；二是组织病理学、胃黏膜完整性，抑制胃酸，清除自由基，提高ATPase，和其他一些有益于胃黏膜的防御因素检测结果，均证实该“成分组方”发挥了元胡止痛片治疗溃疡型胃痛相一致的功效。③元胡止痛片治疗胃痛的作用机制可能与其主成分即延胡索乙素和欧前胡素促进胃溃疡粘膜愈合与其上调乙酰胆碱酯酶活力、下调乙酰胆碱、降低H~+-K~+ATPase和抑制胃酸多因素有关。④成分组方的有效特性为元胡止痛片的二次开发或新药创制提供新的思路和重要的实验依据。⑤首次采用外周D2受体拮抗剂观察到成分组方失去功效，而母方依然有效。可见成分组方的药物靶点是外周D2受体，母方中尚存作用于其它靶点发挥治疗溃疡型胃痛的有效成分。综上，元胡止痛片中存在已知的化学成分至少十余种，故不能排除更多成分组成的“成分组方”产生更好的功效，或还有更复杂的机制尚需进一步研究。
Purpose：
Study of active ingredients and mechanisms for the yuanhu analgesia tablet astraditional Chinese medicine treatment of gastric ulcer.Methods:
In vitro and in vivo, combination use of MTT, pathological examination, colorimetricmethod, enzyme-linked immunosorbent assay, computer-aided drug design, RT-PCR anddopamine D2receptor antagonist domperidone for the study of active ingredients andmechanisms for the yuanhu analgesia tablet as traditional Chinese medicine treatment ofgastric ulcer.
Results:
①Yuanhu analgesia tablet (YAT) and ingredients component (IC) promoted theproliferation of gastric mucosa cell. pathological examination demonstrated that YAT and IC-I promoted proliferation of gastric mucosa cell in rats with gastric ulcer induced byacetic acid. in vitro, compared to the normal control group,3μg/ml tetrahydropalmatine(THP) promoted GES-1proliferation14.7%(P<0.05).2.4×10~(-1)μg/ml imperatorin (IMP)promoted GES-1proliferation12.4%(P<0.05).100μg/ml YAT promoted GES-1proliferation52.1%(P<0.05). Compared to the control group damaged by8%ethanol for1h,3μg/ml THP promoted GES-1proliferation26.5%(P<0.05).2.4μg/ml promoted GES-1proliferation26.9%(P<0.05).100μg/ml YAT promoted GES-1proliferation27.1%(P<0.05). In vivo, compared to the control group (gastric ulcer in rats induced by aceticacid), PCNA were up regulated in following groups:50mg/kg THP+40mg/kg IMP(T50+I40)(151.2%, P<0.05),50mg/kg THP+20mg/kg IMP (T50+I20)(144.6%,P<0.05),YAT(141.9%, P<0.05). Compared to50mg/kg THP (T50) or40mg/kg IMP (I40), T50+I40up regulated PCNA447.8%(P<0.05) or298.7%(P<0.05), respectively.
②YAT and IC up regulated manydefense factors to protect gastric mucosa.Compared to the gastric ulcer induced by acetic acid control group in rats, SP were upregulated in the following groups: T50+I40(58.6%, P<0.01), T50+I20(40.4%,P<0.01),YAT (41.8%, P<0.01). bFGF were up regulated in the following groups: T50+I40(146.6%, P<0.01), T50+I20(59.0%, P<0.05) and YAT (182.8%, P<0.01).Compared toT50or I40or I20or T50+I20, T50+I40significantly (P<0.05) up regulated bFGF,respectively. This was in line with the results of pathological examination and inhibitinggastric acid. YAT and IC protected the gastric mucosa from the damage caused by absoluteethyl alcohol in rats. Compared to the control group, TSOD were up regulated in thefollowing groups: YAT (125%, P<0.001), T50+I40(127.6%, P<0.001), T50+I20(97.0%,P<0.001). Individually using THP or IMP did not achieve the same effect, respectively.And compared to T50or I20, T50+I40up regulated TSOD60.6%(P<0.05) or70.3%(P<0.05). Compared to the control group, MDA were down regulated in the followinggroups: YAT (46.7%, P<0.05), T50+I40(51.6%, P<0.05). The other treatments did notdown regulated MDA significantly. Compared to the control group, Na+K+-ATPaseactivities were up regulated in the following groups: YAT (43.2%, P<0.05), T50+I40(52.1%, P<0.05). The other treatments did not up regulated Na+K+-ATPase activity significantly. And compared to T50, T50+I40up regulated Na+K+-ATPase activity38.1%(P<0.05). Compared to the control group, Ca~(2+)Mg~(2+)-ATPase activities were up regulatedin the following groups: YAT (47.8%, P<0.05), T50+I40(58.0%, P<0.0001). Comparedto T50, T50+I40up regulated Ca~(2+)Mg~(2+)-ATPase activity37.5%(P<0.05). The othertreatments did not up regulated Ca~(2+)Mg~(2+)-ATPase activity significantly. Compared to thecontrol group, TNOS was up regulated in the following groups: YAT (105.5%, P<0.05),T50+I40(149.2%, P<0.05), T50+I20(94.5%, P<0.05). Individually using THP or IMP didnot achieve the same effect,respectively. Compared to the control group, iNOS was upregulated in the following groups: YAT (115.6%, P<0.01), T50+I40(120.9%, P<0.01),T50+I20(63.4%, P<0.05). Individually using THP or IMP did not achieve the same effect,respectively. Compared to the control group, EGF was up regulated in the followinggroups: YAT (13.7%, P<0.05), T50+I40(19.8%, P<0.01). The other treatments did not upregulated EGF significantly. Compared to the control group, TNF-α was up regulated inthe following groups: YAT (39.6%, P<0.001), T50+I40(44.9%, P<0.01), T50+I20(85.3%,P<0.001), T50(30.6%, P<0.05), I20(36.3%, P<0.05). Compared to T50+I40, T50+I20upregulated TNF-α27.9%(P<0.05).
③IC promoted the healing of gastric ulcer was due to up regulating AHCE, downregulating ACH, inhibiting H~+-K~+ATPase activity and antiacid. In vivo, compared to thecontrol group (gastric ulcer in rats induced by acetic acid), T50+I40increased pH27.0%(P<0.05), decreased H~+-K~+ATPase activity47.9%(P<0.01), up regulated ACHE90.4%(P<0.01) and down regulated ACH37.2%(P<0.05). The other treatments did not achievethe same effect as T50+I40did.
④The protection of IC to gastric mucosa was blocked by domperidone. Compared tothe control group (induced by absolute ethyl alcohol in rats),0.2ml/ratdomperidone+T50+I40did not change TSOD, MDA, Na+K+-ATPase activity andCa~(2+)Mg~(2+)-ATPase activity. However0.2ml/rat domperidone did not block the effect ofT50+I40to TNOS, iNOS, EGF and TNF-α.0.2ml/rat domineering did not block theeffect of YAT to these mechanisms. Compared to control group, PGE2was downregulated in the following groups:0.2ml/rat domineering (45.4%, P<0.001), YAT (28.4%, P<0.05),0.2ml/rat domineering+T50+I40(53.2%, P<0.001).
Conclusions:
①we found that IC promoted the healing of gastric ulcer induced by acetic acid inrats and protected gastric mucosa from the damage caused by absolute ethyl alcohol. Thiswas in line with YAT. However individually using THP or IMP did not achieve the sameeffect as IC did.
②First time discovery that THP and IMP are probably active ingredients of YAT astraditional Chinese medicine treatment of gastric ulcer. There are two reasons:1. THP isfrom rhizoma corydalis and IMP is from radix angelicae. Combination of THP and IMP asIC got a mutual reinforcement of compounds.2. IC achieved the same effect as YAT didto gastric ulcer according to the assays (pathological examination, gastric mucosa cellproliferation, antiacid, scavenging free radical, up regulating ATPase, many defencefactors for gastric mucosa, and dopamine D2receptor antagonist domperidone).
③Mechanisms of YATas traditional Chinese medicine treatment of gastric ulcerprobably via THP and IMP were promoting the healing of gastric ulcer due to upregulating ACHE, down regulating ACH, decreasing H~+-K~+ATPase and antiacid.
④The pharmacologicalmechanisms and actions of IC provided a new thinking andexperiment data for new drug discovery based on YAT.
⑤It was first observed that dopamine D2receptor blocked effect and mechanisms ofIC as treatment of gastric ulcer but did not block YAT. Thus dopamine D2receptor was thetarget of IC. There were many compounds in YAT playing more performance via multipletargets. Above all, there are at least dozens of compounds in YAT. Therefore maybe morecompounds involved in IC achieve better effect, and the pharmacological mechanisms andactions respected to further research..
研究元胡止痛片治疗溃疡型胃痛的物效机制。
方法：
从细胞和整体动物水平，采用MTT、组织病理学、比色法检测、酶联免疫吸附测定、计算机辅助药物设计、RT-PCR以及多巴胺受体阻断剂等多种方法深入探讨元胡止痛片（母方）和延胡索乙素、欧前胡素及其延胡索乙素+欧前胡素（成分组方）治疗溃疡型胃痛的物效机制。
结果：
①母方及其成分组方可促进胃黏膜细胞增殖。组织病理学证实母方和成分组方能够有效促进乙酸致雄性SD大鼠胃黏膜损伤愈合。在体外，与模型组比较，3μg/ml延胡索乙素可促进GES-l细胞增殖14.7%(P<0.05)；2.4×10~(-1)μg/ml欧前胡素促进GES-l细胞增殖12.4%(P<0.05)；100μg/ml母方促进GES-l细胞增殖52.1%(P<0.05)。与8%乙醇损伤1h的GES-1模型组比较，3μg/ml延胡索乙素促进GES-l增殖26.5%(P<0.05)，2.4μg/ml欧前胡素促进GES-l增殖26.9%(P<0.05)，100μg/ml母方促进GES-l增殖27.1%(P<0.05)。在体内，对于乙酸致雄性SD大鼠胃溃疡的作用，与模型组相比，PCNA在以下各组中分别增加，50mg/kg延胡索乙素+40mg/kg欧前胡素组（组方I；151.2%；P<0.05），50mg/kg延胡索乙素+20mg/kg欧前胡素组（组方II组；144.6%；P<0.05），母方组（141.9%；P<0.05）。与50mg/kg延胡索乙素和40mg/kg欧前胡素组比较，组方I组分别上调447.8%(P<0.05)和298.7%(P<0.05)。②母方及其成分组方上调多种防御因素保护胃黏膜。对于乙酸致雄性SD大鼠胃溃疡，与模型组相比，SP在以下几组显著性上升，组方I（58.6%；P<0.01），组方II（40.4%；P<0.01），母方（41.8%；P<0.01)。与模型组相比，bFGF在以下处理组中增加，组方I(146.6%；P<0.01)，组方II(59.0%；P<0.05)和母方(182.8%；P<0.01)。与延胡索乙素或者欧前胡素单用相比或者与组方II相比，组方I均能显著提高bFGF含量(P<0.05)。这与以上组织病理学和抑制胃酸的结果一致。母方和成分组方能够减轻无水乙醇致雄性SD大鼠胃黏膜损伤。这与其清除自由基、维护ATPase、提高NOS以及EGF的作用机制相关。与模型组相比，母方提高总SOD含量125%(P<0.001)，组方I提高127.6%(P<0.001)，组方II提高97.0%(P<0.001)。延胡索乙素或欧前胡素分别单独使用，不能达到母方和成分组方的效果。并且与50mg/kg延胡索乙素，20mg/kg欧前胡素相比，组方I提高总SOD60.6%(P<0.05)和70.3%(P<0.05)。与模型组相比，母方降低MDA46.7%(P<0.05)，组方I降低MDA到51.6%(P<0.05)；组方II，延胡索乙素或欧前胡素分别单独使用，均不能显著性降低MDA。与模型组相比，母方提高Na+K+-ATPase43.2%(P<0.05)，组方I提高52.1%(P<0.05)。与50mg/kg延胡索乙素相比，组方I提高Na+K+-ATPase38.1%(P<0.05)。组方II，延胡索乙素或欧前胡素分别单独使用，均不能显著性提高Na+K+-ATPase。与模型组相比，母方提高Ca~(2+)Mg~(2+)-ATPase47.8%(P<0.05)，组方I提高58.0%(P<0.001)。与50mg/kg延胡索乙素相比，组方I提高Ca~(2+)Mg~(2+)-ATPase37.5%(P<0.05)。组方II，延胡索乙素或欧前胡素分别单独使用，均不能显著性提高Ca~(2+)Mg~(2+)ATPase。与模型组相比，TNOS在以下各组显著性提高：母方(105.5%, P<0.05)，组方I(149.2%, P<0.05)和组方II(94.5%，P<0.05)。延胡索乙素或欧前胡素分别单独使用，均不能显著性上调TNOS。与模型组相比，iNOS在以下用药组显著性提高：母方(115.6%, P<0.01)，组方I(120.9%, P<0.01)和组方II(63.4%，P<0.05)。延胡索乙素或欧前胡素分别单独使用，均不能显著性上调iNOS。与模型组相比，EGF在以下用药组显著性提高：母方(13.7%, P<0.05)，组方I(19.8%, P<0.01)。组方II，延胡索乙素或欧前胡素分别单独使用，均不能显著上调EGF。与模型组相比，TNF-α在以下用药组显著性提高：母方(39.6%, P<0.001)，组方I(44.9%, P<0.01)，组方II(85.3%, P<0.001)，50mg/kg延胡索乙素组(30.6%,P<0.05)，20mg/kg欧前胡素组(36.3%, P<0.05)。与组方I相比，组方II提高TNF-α含量27.9%(P<0.05)。③成分组方促进胃溃疡粘膜愈合与其上调乙酰胆碱酯酶活力、下调乙酰胆碱、降低H~+-K~+ATPase和抑制胃酸有关。对于乙酸致雄性SD大鼠胃溃疡，与模型组相比，组方I升高pH27.0%(P<0.05)，降低H~+-K~+ATPase活力47.9%(P<0.01)，上调乙酰胆碱酯酶活力90.4%(P<0.01)，下调乙酰胆碱37.2%(P<0.05)。其他给药处理组不能达到组方I的这些作用。④成分组方抑制胃黏膜损伤作用可被多潘立酮阻断。与无水乙醇致大鼠胃粘膜损伤模型组相比，组方I+0.2ml/只多潘立酮组的总SOD、MDA、Na+K+-ATPase、Ca~(2+)Mg~(2+)-ATPase均无显著性差异；但不干扰组方I对TNOS、iNOS、TNF-α的作用。0.2ml/只多潘立酮未干扰母方的以上作用机制（总SOD、MDA、Na+K+-ATPase、Ca~(2+)Mg~(2+)-ATPase、TNOS、iNOS、TNF-α）。0.2ml/只多潘立酮未干扰成分组方和母方对EGF的上调作用。与模型组相比，PGE2在以下用药组显著性下降：0.2ml/只多潘立酮组（45.4%，P<0.001），母方（28.4%，P<0.05），组方I+0.2ml/只多潘立酮（53.2%，P<0.001）。
结论：
①发现成分组方可显著促进乙酸所致大鼠胃溃疡损伤的愈合，减轻乙醇诱发的应激性伤害。该效果与元胡止痛片相一致；而且单独使用延胡索乙素或欧前胡素不能达到成分组方的效果。②首次揭示延胡索乙素和欧前胡素极有可能是元胡止痛片治疗溃疡型胃痛的物效成分。其理由，一是源自元胡止痛片的延胡索中延胡索乙素和白芷中欧前胡素，合并组成“成分组方”时具有协同起效的作用，并非化学物质药理作用的简单叠加；二是组织病理学、胃黏膜完整性，抑制胃酸，清除自由基，提高ATPase，和其他一些有益于胃黏膜的防御因素检测结果，均证实该“成分组方”发挥了元胡止痛片治疗溃疡型胃痛相一致的功效。③元胡止痛片治疗胃痛的作用机制可能与其主成分即延胡索乙素和欧前胡素促进胃溃疡粘膜愈合与其上调乙酰胆碱酯酶活力、下调乙酰胆碱、降低H~+-K~+ATPase和抑制胃酸多因素有关。④成分组方的有效特性为元胡止痛片的二次开发或新药创制提供新的思路和重要的实验依据。⑤首次采用外周D2受体拮抗剂观察到成分组方失去功效，而母方依然有效。可见成分组方的药物靶点是外周D2受体，母方中尚存作用于其它靶点发挥治疗溃疡型胃痛的有效成分。综上，元胡止痛片中存在已知的化学成分至少十余种，故不能排除更多成分组成的“成分组方”产生更好的功效，或还有更复杂的机制尚需进一步研究。
Purpose：
Study of active ingredients and mechanisms for the yuanhu analgesia tablet astraditional Chinese medicine treatment of gastric ulcer.Methods:
In vitro and in vivo, combination use of MTT, pathological examination, colorimetricmethod, enzyme-linked immunosorbent assay, computer-aided drug design, RT-PCR anddopamine D2receptor antagonist domperidone for the study of active ingredients andmechanisms for the yuanhu analgesia tablet as traditional Chinese medicine treatment ofgastric ulcer.
Results:
①Yuanhu analgesia tablet (YAT) and ingredients component (IC) promoted theproliferation of gastric mucosa cell. pathological examination demonstrated that YAT and IC-I promoted proliferation of gastric mucosa cell in rats with gastric ulcer induced byacetic acid. in vitro, compared to the normal control group,3μg/ml tetrahydropalmatine(THP) promoted GES-1proliferation14.7%(P<0.05).2.4×10~(-1)μg/ml imperatorin (IMP)promoted GES-1proliferation12.4%(P<0.05).100μg/ml YAT promoted GES-1proliferation52.1%(P<0.05). Compared to the control group damaged by8%ethanol for1h,3μg/ml THP promoted GES-1proliferation26.5%(P<0.05).2.4μg/ml promoted GES-1proliferation26.9%(P<0.05).100μg/ml YAT promoted GES-1proliferation27.1%(P<0.05). In vivo, compared to the control group (gastric ulcer in rats induced by aceticacid), PCNA were up regulated in following groups:50mg/kg THP+40mg/kg IMP(T50+I40)(151.2%, P<0.05),50mg/kg THP+20mg/kg IMP (T50+I20)(144.6%,P<0.05),YAT(141.9%, P<0.05). Compared to50mg/kg THP (T50) or40mg/kg IMP (I40), T50+I40up regulated PCNA447.8%(P<0.05) or298.7%(P<0.05), respectively.
②YAT and IC up regulated manydefense factors to protect gastric mucosa.Compared to the gastric ulcer induced by acetic acid control group in rats, SP were upregulated in the following groups: T50+I40(58.6%, P<0.01), T50+I20(40.4%,P<0.01),YAT (41.8%, P<0.01). bFGF were up regulated in the following groups: T50+I40(146.6%, P<0.01), T50+I20(59.0%, P<0.05) and YAT (182.8%, P<0.01).Compared toT50or I40or I20or T50+I20, T50+I40significantly (P<0.05) up regulated bFGF,respectively. This was in line with the results of pathological examination and inhibitinggastric acid. YAT and IC protected the gastric mucosa from the damage caused by absoluteethyl alcohol in rats. Compared to the control group, TSOD were up regulated in thefollowing groups: YAT (125%, P<0.001), T50+I40(127.6%, P<0.001), T50+I20(97.0%,P<0.001). Individually using THP or IMP did not achieve the same effect, respectively.And compared to T50or I20, T50+I40up regulated TSOD60.6%(P<0.05) or70.3%(P<0.05). Compared to the control group, MDA were down regulated in the followinggroups: YAT (46.7%, P<0.05), T50+I40(51.6%, P<0.05). The other treatments did notdown regulated MDA significantly. Compared to the control group, Na+K+-ATPaseactivities were up regulated in the following groups: YAT (43.2%, P<0.05), T50+I40(52.1%, P<0.05). The other treatments did not up regulated Na+K+-ATPase activity significantly. And compared to T50, T50+I40up regulated Na+K+-ATPase activity38.1%(P<0.05). Compared to the control group, Ca~(2+)Mg~(2+)-ATPase activities were up regulatedin the following groups: YAT (47.8%, P<0.05), T50+I40(58.0%, P<0.0001). Comparedto T50, T50+I40up regulated Ca~(2+)Mg~(2+)-ATPase activity37.5%(P<0.05). The othertreatments did not up regulated Ca~(2+)Mg~(2+)-ATPase activity significantly. Compared to thecontrol group, TNOS was up regulated in the following groups: YAT (105.5%, P<0.05),T50+I40(149.2%, P<0.05), T50+I20(94.5%, P<0.05). Individually using THP or IMP didnot achieve the same effect,respectively. Compared to the control group, iNOS was upregulated in the following groups: YAT (115.6%, P<0.01), T50+I40(120.9%, P<0.01),T50+I20(63.4%, P<0.05). Individually using THP or IMP did not achieve the same effect,respectively. Compared to the control group, EGF was up regulated in the followinggroups: YAT (13.7%, P<0.05), T50+I40(19.8%, P<0.01). The other treatments did not upregulated EGF significantly. Compared to the control group, TNF-α was up regulated inthe following groups: YAT (39.6%, P<0.001), T50+I40(44.9%, P<0.01), T50+I20(85.3%,P<0.001), T50(30.6%, P<0.05), I20(36.3%, P<0.05). Compared to T50+I40, T50+I20upregulated TNF-α27.9%(P<0.05).
③IC promoted the healing of gastric ulcer was due to up regulating AHCE, downregulating ACH, inhibiting H~+-K~+ATPase activity and antiacid. In vivo, compared to thecontrol group (gastric ulcer in rats induced by acetic acid), T50+I40increased pH27.0%(P<0.05), decreased H~+-K~+ATPase activity47.9%(P<0.01), up regulated ACHE90.4%(P<0.01) and down regulated ACH37.2%(P<0.05). The other treatments did not achievethe same effect as T50+I40did.
④The protection of IC to gastric mucosa was blocked by domperidone. Compared tothe control group (induced by absolute ethyl alcohol in rats),0.2ml/ratdomperidone+T50+I40did not change TSOD, MDA, Na+K+-ATPase activity andCa~(2+)Mg~(2+)-ATPase activity. However0.2ml/rat domperidone did not block the effect ofT50+I40to TNOS, iNOS, EGF and TNF-α.0.2ml/rat domineering did not block theeffect of YAT to these mechanisms. Compared to control group, PGE2was downregulated in the following groups:0.2ml/rat domineering (45.4%, P<0.001), YAT (28.4%, P<0.05),0.2ml/rat domineering+T50+I40(53.2%, P<0.001).
Conclusions:
①we found that IC promoted the healing of gastric ulcer induced by acetic acid inrats and protected gastric mucosa from the damage caused by absolute ethyl alcohol. Thiswas in line with YAT. However individually using THP or IMP did not achieve the sameeffect as IC did.
②First time discovery that THP and IMP are probably active ingredients of YAT astraditional Chinese medicine treatment of gastric ulcer. There are two reasons:1. THP isfrom rhizoma corydalis and IMP is from radix angelicae. Combination of THP and IMP asIC got a mutual reinforcement of compounds.2. IC achieved the same effect as YAT didto gastric ulcer according to the assays (pathological examination, gastric mucosa cellproliferation, antiacid, scavenging free radical, up regulating ATPase, many defencefactors for gastric mucosa, and dopamine D2receptor antagonist domperidone).
③Mechanisms of YATas traditional Chinese medicine treatment of gastric ulcerprobably via THP and IMP were promoting the healing of gastric ulcer due to upregulating ACHE, down regulating ACH, decreasing H~+-K~+ATPase and antiacid.
④The pharmacologicalmechanisms and actions of IC provided a new thinking andexperiment data for new drug discovery based on YAT.
⑤It was first observed that dopamine D2receptor blocked effect and mechanisms ofIC as treatment of gastric ulcer but did not block YAT. Thus dopamine D2receptor was thetarget of IC. There were many compounds in YAT playing more performance via multipletargets. Above all, there are at least dozens of compounds in YAT. Therefore maybe morecompounds involved in IC achieve better effect, and the pharmacological mechanisms andactions respected to further research..
引文
[1] Snowden FM. Emerging and reemerging diseases: a historical perspective[J].Immunol.2008,225(1):9-26.
[2] Chan FKL, Lau JYW. Peptic ulcer disease[M]. In: Feldman M, Friedman LS, BrandtLJ, eds. Sleisenger&Fordtran's Gastrointestinal and Liver Disease.9th ed.Philadelphia, Pa: Saunders Elsevier.2010:chap53.
[3] Prof Peter Malfertheiner, Francis KL Chan, Kenneth EL McColl. Peptic ulcerdiseases[J]. Lancet.2009,374:1449-61.
[4]杨云珍,刘素珍,吴世红,张永平.消化性溃疡3837例流行病学研究[J].世界华人消化杂志,1998,6(11):971.
[5]李平,薛红仙,周国华等.化性溃疡临床流行病学调查[J].临床军医杂志,2000,28(1),44.
[6]田培兴.太原地区武警士兵上消化道疾病发病分析(附2000例胃镜检查结果)[J].临床医药实践,2004,13(6),454.
[7]郑芝田.消化性溃疡病[M].北京人民卫生出版社,1998,12.
[8]王苏丽,周毅,王婧,姜莉.中国军人在维和境遇下消化性溃疡的临床研究[J].华北国防医药,22(4):364-365.
[9]李学军,宫姝宁,王志敏.青年士兵消化性溃疡病相关因素分析[J].北京军药,2000,12(6):394.
[10] L Stellin, F Meneghin. Acute gastroduodenal lesions and stress[J]. G Chir.1997,18(10):728-31.
[11]马红英,杨虹,刘立新等.驻某地海军部队消化性溃疡流行病学浅析[J].解放军预防医学杂志,1995,13(6):462-463.
[12]王晓君.军人消化性溃疡的流行病学特点及防治[J].解放军医学杂志,2006,31(2):206-208.
[13] Kato, Ikuko, Abraham M. Y. Nomura, Grant N. Stemmermann and Po-HuangChyou. A Prospective Study of Gastric and Duodenal Ulcer and Its Relation toSmoking, Alcohol, and Diet[J]. American Journal of Epidemiology.1992,135(5):521-530.
[14] Salih, Barik, M Fatih Abasiyanik, Nizamettin Bayyurt, Ersan Sander. H pyloriinfection and other risk factors associated with peptic ulcers in Turkish patients: Aretrospective study[J]. World J Gastroenterol.2007,13(23):3245-8.
[15] Kenneth Thorsen, Jon Arne S reide, Jan Terje Kval y, Tom Glomsaker, KjetilS reide. World J Gastroenterol.2013,19(3):347–354.
[16] Kurata Ph.D., M.P.H., John H., Nogawa, Aki N. M.S."Meta-analysis of RiskFactors for Peptic Ulcer: Nonsteroidal Antiinflammatory Drugs, Helicobacter pylori,and Smoking"[J]. Journal of Clinical Gastroenterology,1997,24(1):2-17.
[17] Tsu-Hui Shiao, Chia-Jen Liu, Jiing-Chyuan Luo, Kang-Cheng Su, Yuh-Min Chen,Tzeng-Ji Chen, Kun-Ta Chou, Guang-Ming Shiao, Yu-Chin Lee. Sleep Apnea andRisk of Peptic Ulcer Bleeding: A Nationwide Population-based Study[J]. AM J Med.2013,126(3):249-255.
[18] C. Musumba, A. Jorgensen3, L. Sutton, D. Van Eker1, J. Moorcroft, M. Hopkins, D.M. Pritchard, M. Pirmohamed. ALIMENT PHARM THERAP.2012,36(1):48-56.
[19] Hisato Deguchi, Keiji Yasukawa, Toshihide Yamasaki, Fumiya Mito, YuichiKinoshita, Tatsuya Naganuma, Suguru Sato, Mayumi Yamato, Kazuhiro Ichikawa,Kiyoshi Sakai, Hideo Utsumi, Ken-ichi Yamada. Nitroxides prevent exacerbation ofindomethacin-induced gastric damage inadjuvant arthritis rats[J]. FREE RADICALBIO MED.2011(51):1799-1805.
[20] P. Juillerat1, S. Schneeweiss, E. F. Cook, A. N. Ananthakrishnan, H. Mogun, J. R.Korzenik. Drugs that inhibit gastric acid secretion may alter the course ofinflammatory bowel disease[J]. ALIMENT PHARM THERAP.2012,36(3):239-247.
[21] Jia Wu, Song Xu, Yongliang Zhu. Helicobacter pylori CagA: A Critical Destroyer ofthe Gastric Epithelial Barrier[J]. DIGEST DIS SCI. DOI:10.1007/s10620-013-2589-x.
[22] Hobsley M, Tovey F I. Helicobacter pylori: the primary cause of duodenal ulcerationor a secondary infection?[J]. World Journal of Gastroenterology,2001,7(2):149-151.
[23] Genta R M, Kinsey R S, Singhal A, et al. Gastric foveolar metaplasia and gastricheterotopia in the duodenum: no evidence of an etiologic role for Helicobacterpylori[J]. Human pathology.2010,41(11):1593-1600.
[24] Bauer B, Meyer T F. The human gastric pathogen Helicobacter pylori and itsassociation with gastric cancer and ulcer disease[J]. Ulcers,2011, doi:10.1155/2011/340157.
[25] Muraoka S, Miura T. Metabolism of non-steroidal anti-inflammatory drugs byperoxidase: implication for gastrointestinal mucosal lesions][J]. Yakugaku zasshi: JPharmaceutical Society of Japan,2007,127(4):749-756.
[26] Bjarnason I, Scarpignato C, Takeuchi K, et al. Determinants of the short‐termgastric damage caused by NSAIDs in man[J]. Alimentary pharmacology&therapeutics,2007,26(1):95-106.
[27] Lanza FL, Chan FK, Quigley EM, et al. Guidelines for p revention of NSA ID-related ulcer comp lications [J]. Am J Gastroenterol,2009,104:728-738.
[28] Thorsen K, S reide J A, Kval y J T, et al. Epidemiology of perforated peptic ulcer:Age-and gender-adjusted analysis of incidence and mortality[J]. WORLD JGASTROENTERO,2013,19(3):347-354.
[29] Salih B A, Abasiyanik M F, Bayyurt N, et al. H pylori infection and other riskfactors associated with peptic ulcers in Turkish patients: A retrospective study[J].WORLD J GASTROENTERO,2007,13(23):3245-3248.
[30] Sondashi K J, Odimba B F K, Kelly P. A Cross-sectional Study on FactorsAssociated With Perforated Peptic Ulcer Disease in Adults Presenting to UTH,Lusaka[J]. Medical Journal of Zambia,2012,38(2):15-22.
[31] Musumba C. Letter: peptic ulcer bleeding in patients with cirrhosis[J]. ALIMENTPHARM THERAP.2012,36(6):597-598.
[32] Hernández-Díaz S, Martín-Merino E, Rodríguez L A G. Risk of Complications Aftera Peptic Ulcer Diagnosis: Effectiveness of Proton Pump Inhibitors[J]. DIGEST DISSCI,2013:1-10.
[33]陈韶华,厉有名.酒精性胃黏膜损伤的研究进展[J].国际消化病杂志.2006,26(4);249-250.
[34] Linea C, Sinagra E, La Seta F, et al. Acquired double pylorus, due to penetratinggastric ulcer, presenting with melena[J]. World Journal of GastrointestinalEndoscopy,2012,4(3):94-95.
[35]罗燕军,于皆平.胃黏膜血流变化的影响因素[J].世界华人消化杂志.2001,9(6);671-674.
[36] Chen S, Gao H, Wang J, et al. Su1632Evaluation of Prokinetic Drugs on GastricEmptying of Solid in Patients With Postprandial Distress Syndrome[J].Gastroenterology,2012,142(5): S468-S469.
[37] Wu D Y, Guo M, Gao Y S, et al. Clinical effects of psychological intervention anddrug therapy against peptic ulcer[J]. Asian Pacific journal of tropical medicine,2012,5(10):831-833.
[38] Peptic ulcer. A.D.A.M. Medical Encyclopedia. U.S. National Library of Medicine.2011, http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001255/.
[39] Tarnawski A, Ahluwalia A, K Jones M. Gastric Cytoprotection BeyondProstaglandins: Cellular and Molecular Mechanisms of Gastroprotective and UlcerHealing Actions of Antacids[J]. Current Pharmaceutical Design,2013,19(1):126-132.
[40] Davenport H W. The gastric mucosal barrier[J]. Digestion,2009,5(3-4):162-165.
[41][41]房殿春,彭志红.胃黏膜屏障功能研究概况[J].现代消化介入及诊疗,2007,12(1);48-52.
[42] Phillipson M. Acid transport through gastric mucus[J]. UPSALA J MED SCI,2004,109(1):1-24.
[43]王烈泉,耿立梅.消化性溃疡[M].北京中国医药科技出版社.2005;23-24.
[44] Li, WF, Jiang, JG, Chen, J. Chinese medicine and its modernizationdemands[J].ARCHIVES OF MEDICAL RESEARCH,2008,39(2)246-251.
[45] Rohit Chugh, Veena Sangwan, Satish P. Patil, Vikas Dudeja,Rajinder K.Dawra,Sulagna Banerjee,Robert J. Schumacher,Bruce R. Blazar,Gunda I.Georg,Selwyn M. Vickers,Ashok K. Saluja. A Preclinical Evaluation of Minnelideas a Therapeutic Agent Against Pancreatic Cancer[J]. Sci Transl Med,2012,4:156-162.
[46] Song H, Guo T, Zhang R, Zheng C, Ma Y, Li X, Bi K, Tang X.Preparation of thetraditional Chinese medicine compound recipe heart-protecting musk pH-dependentgradient-release pellets[J].Drug Dev Ind Pharm,2002,28(10):1261-73.
[47] L. Wang, Zhou, G.B., Liu, P., Song, J.H., Liang, Y., Yan, X.J., et al., Dissection ofmechanisms of Chinese medicinal prescription Realgar-Indigo naturalis as aneffective treatment for promyelocytic leukemia[J]. Proc. Natl. Acad. Sci. U. S.A.,2008,105:4826-4831.
[48]王四旺,谢艳华,孙纪元.中药现代化与“揭示中药物效成分学”[J].中国医学月刊,2002;1(9):743-745.
[49]王四旺.“中药组分”与“揭示中药物效成分”[J].第四军医大学学报,2008;29(18):2280-2284.
[50]王四旺,谢艳华,曹蔚.揭示中药物效成分研究与方法学[M].军事医学科学出版社,2012.
[51] DiMasi, J.A. et al. The price of innovation: new estimates of drug developmentcosts[J]. J. Health Economics,2003,22,151-185.
[52] Yu, Chien-Yu Chen, Chih-Ho Hsu, Hsin-Yi Chen,Kuei-Jen Lee, Fuu-Jen Tsai,Current developments of computer-aided drug design[J].2010,323(5):243-256.
[53] Wen-TsaiSung,Yu-FengLiu. Energy minimumtheorembasedonAGA,Lyapunovandforcefieldf or CADD techniques[J].2012,36(5):239-246.
[54]陈擎文.《伤寒论》的“方-证要素”对应体系及其神经网络数学模型的构建[D].北京中医药大学,2011.
[55] Hou T, Xu X. A new molecular simulation software package–Peking UniversityDrug Design System (PKUDDS) for structure-based drug design[J]. Journal ofMolecular Graphics and Modelling,2001,19(5):455-465.
[56] Chen C Y C. Chemoinformatics and pharmacoinformatics approach for exploringthe GABA-A agonist from Chinese herb suanzaoren[J]. Journal of the TaiwanInstitute of Chemical Engineers,2009,40(1):36-47.
[57] Chen C Y C. Insights into the suanzaoren mechanism—From constructing the3Dstructure of GABA-A receptor to its binding interaction analysis[J]. Journal of theChinese Institute of Chemical Engineers,2008,39(6):663-671.
[58] Qiao X, Hou T, Zhang W, et al. A3D structure database of components fromChinese traditional medicinal herbs[J]. Journal of chemical information andcomputer sciences,2002,42(3):481-489.
[59] Xu X. New concepts and approaches for drug discovery based on traditionalChinese medicine[J]. Drug Discovery Today: Technologies,2006,3(3):247-253.
[60] Tang Y, Zhu W, Chen K, et al. New technologies in computer-aided drug design:toward target identification and new chemical entity discovery[J]. Drug discoverytoday: technologies,2006,3(3):307-313.
[61] Jorgensen W L. The many roles of computation in drug discovery[J]. Science,2004,303(5665):1813-1818.
[62] Chen C Y C. Virtual screening and drug design for PDE-5receptor from traditionalChinese medicine database[J]. Journal of Biomolecular Structure and Dynamics,2010,27(5):627-640.
[63] Chen C Y C. Virtual screening and drug design for PDE-5receptor from traditionalChinese medicine database[J]. Journal of Biomolecular Structure and Dynamics,2010,27(5):627-640.
[64]缪珠雷,李玉虎,包寅,徐栋梁,张辉,王易.计算机辅助设计抗感染中药复方的实验研究.中草药,2009,40(10):1602-1607.
[65]陈守强.丁书文教授用药规律的计算机辅助分析[D].山东中医药大学,2002.
[66]刘保兴.黄精赞育胶囊优选方改善精子运动能力的初步机理研究[D].北京中医药大学,2005.
[67]张林.计算机辅助古代肝病方剂组方规律的研究及古代肝病方剂数据库初探[D].北京中医药大学,2004.
[68]黄河舟.计算机辅助信息处理技术在药物色谱分析中的应用[D].第二军医大学,2004.
[69]马晓琼.人参化学物质基础分析方法研究[D].中国科学院大脸化学物理研究所,2005.
[70]王毅.现代中药创制设计方法学及关键技术研究[D].浙江大学,2007.
[71]沈杰.药物ADMET理论预测方法开发和靶向雌激素受体的药物设计研究[D].华东理工大学,2011.
[72]徐俊.运用CADD探讨穿心莲内酯衍生物抑制ALP_省略_萄糖苷酶的构效关系及构建其跨膜[D].暨南大学,2010.
[73]龙伟.中药复方黄连解毒汤药效物质基础的计算机虚拟筛选研究[D].中国协和医科大学研究生院,2008.
[74]中华人民共和国药典(第一部,2010版)[M].北京,中国医药科技出版,2010.
[75]郑汉臣,蔡少青.药用植物学与生药学(第4版)[M]..北京,人民卫生出版社.2006;284.
[76]王浴生,邓文龙,薛春.中药药理与应用[M].北京;人民卫生出版社,1998.
[77]张笑恺.元胡止痛片主活性成分分析及其药代动力学研究[D].第四军医大学,2012.
[78] Min Q,Bai Y T,Shu S J,et a1.Protective effect of dl-tetrahydropalmatine on liverinjury induced by carbon tetrachloride in mice[J].China J Chin MaterMed,2006,31(6);483-484.
[79] Lin M T,Chueh F Y,Hsich M T.The hypothermic effects of dl-tetrahydropalmatinein rats [J].Neurosci Lett,2001(315);53-56.
[80] Wai C L,Hui Z,Michael H,el a1.Anxiolytic-like action of orally adm inistereddl-tetrahydropalmatine in elevated plus-maze[J].Prog Neuro-psychopharmacol BiolPsychiat,2003(27);775-779.
[81] Chang C K,Lin M T. dl-Tetrahydropalmatine may act through inhibition ofamygdaloid release of dopamine to inhibit an epileptic attack in rats[J]. NeurosciLett,2001,307,163-166.
[82] LIU Y, WU C, GONG Z. An Experimental Study on the Inhibited Effects ofL-Tetrahydropalmatine on Oxycodone-induced Physical Dependence in Mice andRats[J].Chin J Dr ug Abuse Prey Treat,2005(3);150-152.
[83] Hsieh C L, Liao E T, Chiang S Y, et al. Effect of Rhizoma Corydalis on focalcerebral infarct in ischemia-reperfusion injured rats[J]. Acta Pharmacologica Sinica,2001,22(12):1143-1148.
[84]]Jing T, Kun J, Kunjie L, et al. Determination of Trantinterol Enantiomers in RatLiver S9Fraction by Pre-column Derivatization HPLC[J]. China Pharmacist.2011,3:339-342..
[85]宫照东.四氢巴马汀对雌性大鼠血清中催乳素水平影响的研究[J].中医药学刊,2003,21(5):694-694.
[86] Guo W, Sun J, Jiang L, et al. Imperatorin Attenuates LPS-Induced Inflammation bySuppressing NF-κB and MAPKs Activation in RAW264.7Macrophages[J].Inflammation,2012,35(6):1764-1772.
[87] Ban H S, Lim S S, Suzuki K, et al. Inhibitory effects of furanocoumarins isolatedfrom the roots of Angelica dahurica on prostaglandin E2production[J]. Plantamedica,2003,69(05):408-412.
[88] Hong J J, Shin K H, Lim S S, et al. Lead compounds for anti-inflammatory drugsisolated from the plants of the traditional oriental medicine in Korea[J].Inflammation&Allergy-Drug Targets,2008,7(3):195-202.
[89]嵇杨,曾国前,等.欧芹素乙和异欧芹素乙对小鼠腹腔巨噬细胞体外释放肿瘤坏死因子的一致作用[J].第二军医大学学报,1994,156;511-513.
[90] Márquez N, Sancho R, Ballero M, et al. Imperatorin inhibits T-cell proliferation bytargeting the transcription factor NFAT[J]. Planta medica.2004,70(11):1016-1021.
[91] Sancho R, Márquez N, Gómez-Gonzalo M, et al. Imperatorin inhibits HIV-1replication through an Sp1-dependent pathway[J]. Journal of Biological Chemistry,2004,279(36):37349-37359.
[92] Widelski J, Popova M, Graikou K, et al. Coumarins from Angelica lucidaL.-antibacterial activities[J]. Molecules.2009,14(8):2729-2734.
[93] Patra A K. An Overview of Antimicrobial Properties of Different Classes ofPhytochemicals[M]. Dietary Phytochemicals and Microbes. Springer Netherlands,2012:1-32.
[94] Luszczki J J, Wojda E, Andres-Mach M, et al. Anticonvulsant and acute neurotoxiceffects of imperatorin, osthole and valproate in the maximal electroshock seizureand chimney tests in mice: a comparative study[J]. Epilepsy research,2009,85(2):293-299.
[95] Tzu-Yu Lin, Cheng-Wei Lu, Wei-Jan Huang, Su-Jane Wang. Lin T Y, Lu C W,Huang W J, et al. Osthole or imperatorin‐mediated facilitation of glutamate releaseis associated with a synaptic vesicle mobilization in rat hippocampal glutamatergicnerve endings[J]. Synapse,2010,64(5):390-396.
[96] Li L, HongJun Y, YongQing X, et al. Effect of Chuanxiong Fangfeng Baizhiprescription on isolated rabbit basilar artery[J]. China Journal of Chinese MateriaMedica,2009,34(11):1415-1417.
[97] Luszczki J J, Wojda E, Andres-Mach M, et al. Anticonvulsant and acute neurotoxiceffects of imperatorin, osthole and valproate in the maximal electroshock seizureand chimney tests in mice: a comparative study[J]. Epilepsy research,2009,85(2):293-299.
[98]李铁军,徐添颖,芮耀诚,等.欧芹素乙对大鼠脑缺血再灌注损伤的保护作用[J].第二军医大学学报,2004,25(4):431-433.
[99] Santos A P, Moreno P R H. Pilocarpus spp.: a survey of its chemical constituents andbiological activities[J]. Revista Brasileira de Ciências Farmacêuticas,2004,40(2):116-137.
[100] Irungu B N, Mbabub M J, Kiboi D M, et al. In vivo antimalarial and acute toxicityproperties of hexane and chloroform extracts from Clausena anisata (Willd.)Benth[J]. African Journal of Pharmacology and Therapeutics Vol,2012,1(1):24-29.
[101] Bauer R, Xiao P G. Fructus Cnidii Shechuangzi[M].Chromatographic FingerprintAnalysis of Herbal Medicines. Springer Vienna,2011:499-508.
[102] Tang C H, Yang R S, Chien M Y, et al. Enhancement of bone morphogeneticprotein-2expression and bone formation by coumarin derivatives via p38andERK-dependent pathway in osteoblasts[J]. European journal of pharmacology,2008,579(1-3):40-49.
[103] Nisa F, Hermawan A, Murwanti R, et al. Antiproliferative effect of gynuraprocumbens (lour.) Merr. Leaves etanolic extract on7,12-dimethylbenz (a)antracene induced male rat liver[J]. Advanced Pharmaceutical Bulletin,2012,2:99-106.
[104] Biskup E, Lojkowska E. Evaluation of biological activities of Rhaponticumcarthamoides extracts[J]. J Med Plants Res,2009,3(12):1092-1098.
[105] Ivey F D, Wang L, Demirbas D, et al. Development of a fission yeast-basedhigh-throughput screen to identify chemical regulators of cAMPphosphodiesterases[J]. Journal of biomolecular screening,2008,13(1):62-71.
[106]梁新丽,廖正根,王光发,等.白芷提取物与延胡索总碱配伍对延胡索乙素在大鼠体内药代动力学的影响[J].药学学报,2009；4(6);645-650.
[107]祝婧云,廖正根,陈绪龙,等.元胡白芷有效组分配伍对延胡索乙素小肠吸收的影响[J].江西中医学院学报,2009；21(3);56-59.
[108]金国章.中药延胡索研究中的新发现[M].上海;科学技术出版社.2001;71-1l1.
[109]金国章.胡江元.颅痛定(rotundine)的镇痛作用机制与多巴胺受体.药理学进展[M].北京;科学出版社,1999;64.
[110] Wang C, Li S, Li C, et al. Molecular cloning, expression profile, polymorphism andthe genetic effects of the dopamine D1receptor gene on duck reproductive traits[J].Molecular biology reports,2012,39(9):9239-9246.
[111] Popesku J T, Navarro-Martín L, Trudeau V L. Evidence for alternative splicing of adopamine D2receptor in a teleost[J]. Physiological and Biochemical Zoology,2011,84(2):135-146.
[112] Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamineD3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments ofworking memory, attention set-shifting, and recognition memory in the mouse[J].Psychopharmacology,2013,226(1):91-100.
[113] Seeman P. Historical overview: introduction to the dopamine receptors[M].TheDopamine Receptors. Humana Press,2010:1-21.
[114] Rondou P, Haegeman G, Van Craenenbroeck K. The dopamine D4receptor:biochemical and signalling properties[J]. Cellular and molecular life sciences,2010,67(12):1971-1986.
[115]朱子涛,傅雨,胡国渊,金国章.左旋千金藤啶碱D1激动-D2阻滞作用引起伏核双相放电活动的电生理研究.生理学报,2000,(2):123-130.
[116] Motawi T K, Hamed M A, Hashem R M, et al. Protective and Therapeutic Effects ofArgyreia speciosa against Ethanol-Induced Gastric Ulcer in Rats[J]. Zeitschrift furNaturforschung C-Journal of Biosciences,2012,67(1):47-57.
[117]李和泉,常青,聂桦,等.多巴胺对大鼠胃粘膜表层微循环血液灌注的影响[J].中国医科大学学报,1989,18(3):177-180.
[118] Eliassi A, Aleali F, Ghasemi T. PERIPHERAL DOPAMINE D2‐LIKERECEPTORS HAVE A REGULATORY EFFECT ON CARBACHOL‐,HISTAMINE‐A ND PENTAGASTRIN‐STIMULATED GASTRIC ACIDSECRETION[J]. Clinical and Experimental Pharmacology and Physiology,2008,35(9):1065-1070.
[119] Dawirs R R, Teuchert‐N oodt G. A novel pharmacological concept in an animalmodel of psychosis[J]. Acta Psychiatrica Scandinavica,2001,104(s408):10-17.
[120] Lee T H, Kim K H, Lee S O, et al. Tetrahydroberberine, an isoquinoline alkaloidisolated from corydalis tuber, enhances gastrointestinal motor function[J]. Journal ofPharmacology and Experimental Therapeutics,2011,338(3):917-924.
[121]杨倩,王四旺.延胡索乙素与白芷总香豆素,总挥发油配伍药效学比较研究[J].现代生物医学进展,2009,9(15):2814-2816.
[122]何美蓉,林劲秋,宋于刚.选择性COX-2抑制剂对实验性大鼠胃溃疡愈合及胃酸分泌的影响[J].南方医科大学学报,2007,27(7):91-91.
[123] DiMasi J A, Hansen R W, Grabowski H G. The price of innovation: new estimates ofdrug development costs[J]. Journal of health economics,2003,22(2):151-186.
[124] Xiaofeng Liu, Sisheng Ouyang, Biao Yu, Kai Huang, Yabo Liu, Jiayu Gong, SisuanZheng, Zhihua Li, Honglin Li, Hualiang Jiang. PharmMapper Server: a web serverfor potential drug target identification via pharmacophore mapping approach.Nucleic Acids Research,2010,38, W609-W614.
[125] Zhuo Chen, Xin Wang, Weiping Zhu, Xianwen Cao, Linjiang Tong, Honglin Li, HuaXie, Yufang Xu, Shaoying Tan, Dong Kuang, Jian Ding, and Xuhong Qian.Acenaphtho[1,2-b]pyrrole-Based Selective Fibroblast Growth Factor Receptors1(FGFR1) Inhibitors: Design, Synthesis, and Biological Activity. J. Med. Chem.,2011,54(11),3732-3745.
[126] Liu E S L, Ye Y N, Shin V Y, et al. Interaction of cigarette smoking withcyclooxygenase-2on ulcerative colitis-associated neoplasia in mice[J]. Cancerinvestigation,2007,25(8):750-757.
[127] Zhang W, Zheng S B, Zhuang Y, et al. H+‐K+‐ATPase expression in humanparietal cell and gastric acid secretion in elderly[J]. Journal of Digestive Diseases,2013, DOI:10.1111/1751-2980.12055.
[128] Nguyen N, Kozer-Gorevich N, Gliddon B L, et al. Independent trafficking of theKCNQ1K+channel and H+-K+-ATPase in gastric parietal cells from mice[J].American Journal of Physiology-Gastrointestinal and Liver Physiology,2013,304(2): G157-G166.
[129] Fang H B, Jin L, Zai W C, et al. Synthesis and H+/K+-ATPase Inhibitory Activity of2-Phenyl-6,7-Dihydrobenzofuran-4(5H)-one Oxime Ether Derivatives[J].Advanced Materials Research,2013,634:1192-1195.
[130] Rasheed N, Ahmad A, Singh N, et al. Differential response of A68930and sulpiridein stress-induced gastric ulcers in rats[J]. European journal of pharmacology,2010,643(1):121-128.
[131] Thany S H, Tricoire-Leignel H, Lapied B. Identification of Cholinergic SynapticTransmission in the Insect Nervous System[M].Insect Nicotinic AcetylcholineReceptors. Springer New York,2010:1-10.
[132] Becker D E. Basic and Clinical Pharmacology of Autonomic Drugs[J]. Anesthesiaprogress,2012,59(4):159-169.
[133] Lotti V J, Chang R S L, Kling P J, et al. Evidence that cholecystokinin octapeptide(CCK-8) acts as a potent, full agonist on gastrin receptors for acid secretion in theisolated mouse stomach: lack of antagonism by the specific CCK antagonistasperlicin[J]. Digestion,2009,35(3):170-174.
[134] LI Y, WANG J H, LAO S X, et al. Inhibitory action of dl-tetrahydropalmatine ongastric acid secretion in vitro [J][J]. Chinese Pharmacological Bulletin,1993,(1):44-47.
[135] KUO-CHANG T, BIN H S U. STUDIES ON THE PHARMACOLOGICALACTIONS OF CORYDALIS Ⅶ. INFLUENCE OF CORYDALIS B ON GASTRICSECRETION AND ITS HYPNOTIC ACTION IN DOGS[J]. Acta PharmaceuticaSinica,1962,(3):145-150.
[136] Brzozowski T, Konturek P C, Konturek S J, et al. Effect of local application ofgrowth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1and-2[J]. Digestion,2001,64(1):15-29.
[137]郭宏.多巴胺受体激动剂与多巴胺神经元的生长和发育[D].中国科学院研究生院(上海生命科学研究院),2003.
[138]杨倩,王四旺.延胡索乙素与白芷总香豆素,总挥发油配伍药效学比较研究[J].现代生物医学进展,2009,9(15):2814-2816.
[139] Wang L, Zhou G B, Liu P, et al. Dissection of mechanisms of Chinese medicinalformula Realgar-Indigo naturalis as an effective treatment for promyelocyticleukemia[J]. Proceedings of the National Academy of Sciences,2008,105(12):4826-4831.
[140] Anonymous. The Inner Canon of Emperor Huang[M]. Chinese Medical AncientBooks Publishing House,Beijing,2003.
[141] López-Armada M J, Valcárcel-Ares M N, Riveiro-Naveira R R, et al. Nitric Oxideand the Respiratory Chain in Synovial Cells and Chondrocytes[M].Studies onArthritis and Joint Disorders. Springer New York,2013:49-66.
[142] Luiz-Ferreira A, Almeida A C A, Cola M, et al. Mechanisms of the gastricantiulcerogenic activity of Anacardium humile St. Hil on ethanol-induced acutegastric mucosal injury in rats[J]. Molecules,2010,15(10):7153-7166.
[143] Yi L, Lingshan G, Cui Y, et al. A preliminary study on protective effect ofL-citrulline against ischemia-reperfusion induced gastric mucosal lesions in rat[J].Indian journal of pharmacology,2012,44(1):31-35.
[144] Yu H, Sato E F, Minamiyama Y, et al. Effect of nitric oxide on stress-induced gastricmucosal injury in the rat[J]. Digestion,2009,58(4):311-318.
[145] Qiu B S, Pfeiffer C J, Cho C H. Effects of Chronic Nitric Oxide Synthase Inhibitionin Cold-Restraint and Ethanol-lnduced Gastric Mucosal Damage in Rats[J].Digestion,2009,57(1):60-66.
[146] Szlachcic A, Krzysiek-Maczka G, Pajdo R, et al. The impact of asymmetricdimethylarginine (ADAMA), the endogenous nitric oxide (NO) synthase inhibitor,to the pathogenesis of gastric mucosal damage[J]. Current Pharmaceutical Design,2013,19(1):90-97.
[147] Konturek S K, Ch K P. Role of nitric oxide in the digestive system[J]. Digestion,2009,56(1):1-13.
[148] Zhang G F, Zhang M A, Chen Y R, et al. The roles of endothelin and nitric oxide ingastric mucosa injuries in rats with endotoxemia[J]. World Chin J Digestol,2000,8:24-28.
[149] Lundberg J O, Weitzberg E. Biology of nitrogen oxides in the gastrointestinaltract[J]. Gut,2013,62(4):616-629.
[150]郭津生,古永亮,王吉耀,等.结构型与诱生型一氧化氮合酶在大鼠胃溃疡模型中的表达和活性变化[J].世界华人消化杂志,2001,9(3):288-292.
[151] Brzozowski T, Konturek S J, Drozdowicz D, et al. Healing of chronic gastriculcerations by L-arginine[J]. Digestion,2009,56(6):463-471.
[152] von der Leyen H E, Mügge A, Hanefeld C, et al. A prospective, single-blind,multicenter, dose escalation study of intracoronary iNOS lipoplex (CAR-MP583)gene therapy for the prevention of restenosis in patients with de novo or restenoticcoronary artery lesion (REGENT I Extension)[J]. Human gene therapy,2010,22(8):951-958.
[153] Perron N, Tremblay E, Ferretti E, et al. Deleterious effects of indomethacin in themid-gestation human intestine[J]. Genomics,2013,101(3):171-177.
[154] Choi S C, Oh H M, Park J S, et al. Soluble Factor from Murine Bladder Tumor-2Cell Elevates Nitric Oxide Production in Macrophages and Enhances theTaxol-Mediated Macrophage Cytotoxicity on Tumor Cells: ORIGINAL ARTICLE[J]. Cancer investigation,2003,21(5):708-719.
[155] Sosroseno W, Bird P S, Seymour G J. Effect of exogenous nitric oxide on murineimmune response induced by Aggregatibacter actinomycetemcomitanslipopolysaccharide[J]. Journal of periodontal research,2009,44(4):529-536.
[156] Polli-Lopes A C, Estofolete C F, Oliani S M, et al. Myenteric denervation in gastriccarcinogenesis: differential modulation of nitric oxide and annexin-A1[J].International journal of clinical and experimental pathology,2013,6(1):13-23.
[157] Xaus J, Comalada M, Valledor A F, et al. LPS induces apoptosis in macrophagesmostly through the autocrine production of TNF-α[J]. Blood,2000,95(12):3823-3831.
[158] McKinney L C, Aquilla E M, Coffin D, et al. Ionizing Radiation Potentiates theInduction of Nitric Oxide Synthase by Interferon‐γ and/or Lipopolysaccharide inMurine Macrophage Cell Lines: Role of Tumor Necrosis Factor‐α [J]. Annals of theNew York Academy of Sciences,2000,899(1):61-68.
[159] Diamantopoulos A P, Hetland H, Hansen A E, et al. Severe deterioration of newlydiagnosed Takayasu arteritis in a patient re-treated with interferon beta-1α forconcomitant longstanding multiple sclerosis[J]. Modern Rheumatology,2012,22(3):474-478.
[160] Ropert C, Almeida I C, Closel M, et al. Requirement of mitogen-activated proteinkinases and IκB phosphorylation for induction of proinflammatory cytokinessynthesis by macrophages indicates functional similarity of receptors triggered byglycosylphosphatidylinositol anchors from parasitic protozoa and bacteriallipopolysaccharide[J]. The Journal of Immunology,2001,166(5):3423-3431.
[161] Li W, Lin J, Adams G L, et al. Expression of inducible nitric oxide synthase (iNOS)in middle ear epithelial cells by IL-1β and TNF-α[J]. International journal ofpediatric otorhinolaryngology,2000,55(2):91-98.
[162] Chairmandurai A R, Kanappa S V, Vadrevu K M, et al. Recombinant HumanEpidermal Growth Factor Alleviates Gastric Antral Ulcer Induced by Naproxen: ANon-steroidal Anti Inflammatory Drug[J]. Gastroenterology Research,2010,3(3):125-133.
[163] Surh Y J, Kundu J K, Li M H, et al. Role of Nrf2-mediated heme oxygenase-1upregulation in adaptive survival response to nitrosative stress[J]. Archives ofpharmacal research,2009,32(8):1163-1176.
[164] Jayakumar A R, Tong X Y, Ospel J, et al. Role of cerebral endothelial cells in theastrocyte swelling and brain edema associated with acute hepatic encephalopathy[J].Neuroscience,2012,218(30):305-316.
[165] Ryter S W, Otterbein L E, Morse D, et al. Heme oxygenase/carbon monoxidesignaling path-ways: Regulation and functional significance[M].Oxygen/NitrogenRadicals: Cell Injury and Disease. Springer US,2002:249-263.
[166] Kitamura Y, Furukawa M, Matsuoka Y, et al. In vitro and in vivo induction of hemeoxygenase‐1in rat glial cells: Possible involvement of nitric oxide production frominducible nitric oxide synthase[J]. Glia,1998,22(2):138-148.
[167] Motterlini R, Foresti R, Bassi R, et al. Endothelial Heme Oxygenase-1Induction byHypoxia MODULATION BY INDUCIBLE NITRIC-OXIDE SYNTHASEANDS-NITROSOTHIOLS[J]. Journal of Biological Chemistry,2000,275(18):13613-13620.
[168] Ishikawa K, Navab M, Lusis A J. Vasculitis, Atherosclerosis, and Altered HDLComposition in Heme-Oxygenase-1-Knockout Mice[J]. International journal ofhypertension,2012,2012:doi:10.1155/2012/948203.
[169] Willis D, Moore A R, Willoughby D A. Heme oxygenase isoform expression incellular and antibody‐mediated models of acute inflammation in the rat[J]. TheJournal of pathology,2000,190(5):627-634.
[170] Haschemi A, Chin B Y, Jeitler M, et al. Carbon monoxide induced PPARγSUMOylation and UCP2block inflammatory gene expression in macrophages[J].PloS one,2011,6(10): e26376.doi:10.1371/journal.pone.0026376.
[171] Yoshimura T, Sugata H. Alcohol scavenges nitric oxide in gastric lumen[J]. NitricOxide,2002,6(3):347-352.
[172] Sakai H, Ohira Y, Tanaka A, Suzuki T, Ikari A, Morii M, Takeguchi N. Inhibition ofsmall-conductance Cl-channels by the interleukin-1beta-stimulated production ofsuperoxide in rabbit gastric parietal cells[J]. J Physiol,2003,551:207-217.
[173] Konturek P C, Kania J, Hahn E G, et al. Ascorbic acid attenuates aspirin-inducedgastric damage: role of inducible nitric oxide synthase[J]. Journal of physiology andpharmacology,2006,57:125.
[174]夏敏,陶嘉泳.乙醇对小鼠胃粘膜的损伤机制[J].新消化病学杂志,1997,5(4):211-212.
[175] Tepperman B L, Chang Q, Soper B D. The involvement of protein kinase C in nitricoxide‐induced damage to rat isolated colonic mucosal cells[J]. British journal ofpharmacology,1999,128(6):1268-1274.
[176] Kato S, Ohkawa F, Ito Y, et al. Role of endothelial nitric oxide synthase inaggravation of indomethacin-induced gastric damage in adjuvant arthritic rats[J]. JPhysiol Pharmacol,2009,60(4):147-155.
[177] Sultana R, Butterfield D A. Brain Protein Oxidation and Modification for Good orfor Bad in Alzheimer’s Disease[M].Neurochemical Mechanisms in Disease.Springer New York,2011:585-605.
[178] Zhi Q, Wang S, Chai M, et al. Transgenic mini-tomato and protection againstalcohol-induced gastric injury[J]. Journal of Genetics and Genomics,2007,34(8):756-763.
[179] Banan A, Zhang L, Fields J Z, et al. PKC-ζ prevents oxidant-induced iNOSupregulation and protects the microtubules and gut barrier integrity[J]. AmericanJournal of Physiology-Gastrointestinal and Liver Physiology,2002,283(4):G909-G922.
[180] Banan A, Zhang L J, Shaikh M, et al. Key role of PLC-γ in EGF protection ofepithelial barrier against iNOS upregulation and F-actin nitration and disassembly[J].American Journal of Physiology-Cell Physiology,2003,285(4): C977-C993.
[181] Puri S, Ray A, Chakravarti A K, et al. A differential dopamine receptor involvementduring stress ulcer formation in rats[J]. Pharmacology Biochemistry and Behavior,1994,47(3):749-752.
[182] Schepp W, Schmidtler J, Tatge C, et al. Effect of substance P and neurokinin A on ratparietal cell function[J]. American Journal of Physiology-Gastrointestinal and LiverPhysiology,1990,259(4): G646-G654.
[183] Yokotani K, Fujiwara M. Effects of substance P on cholinergically stimulated gastricacid secretion and mucosal blood flow in rats[J]. Journal of Pharmacology andExperimental Therapeutics,1985,232(3):826-830.
[184] Perelson A S, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infectedcompartments during combination therapy[J].1997.
[185] Chabner B A, Roberts T G. Chemotherapy and the war on cancer[J]. Nature ReviewsCancer,2005,5(1):65-72.
[186]王光发,廖正根,梁新丽,等. HPLC法同时测定元胡止痛片中3种活性成分的含量[J].中国药房,2009,20(9):672-674.
[2] Chan FKL, Lau JYW. Peptic ulcer disease[M]. In: Feldman M, Friedman LS, BrandtLJ, eds. Sleisenger&Fordtran's Gastrointestinal and Liver Disease.9th ed.Philadelphia, Pa: Saunders Elsevier.2010:chap53.
[3] Prof Peter Malfertheiner, Francis KL Chan, Kenneth EL McColl. Peptic ulcerdiseases[J]. Lancet.2009,374:1449-61.
[4]杨云珍,刘素珍,吴世红,张永平.消化性溃疡3837例流行病学研究[J].世界华人消化杂志,1998,6(11):971.
[5]李平,薛红仙,周国华等.化性溃疡临床流行病学调查[J].临床军医杂志,2000,28(1),44.
[6]田培兴.太原地区武警士兵上消化道疾病发病分析(附2000例胃镜检查结果)[J].临床医药实践,2004,13(6),454.
[7]郑芝田.消化性溃疡病[M].北京人民卫生出版社,1998,12.
[8]王苏丽,周毅,王婧,姜莉.中国军人在维和境遇下消化性溃疡的临床研究[J].华北国防医药,22(4):364-365.
[9]李学军,宫姝宁,王志敏.青年士兵消化性溃疡病相关因素分析[J].北京军药,2000,12(6):394.
[10] L Stellin, F Meneghin. Acute gastroduodenal lesions and stress[J]. G Chir.1997,18(10):728-31.
[11]马红英,杨虹,刘立新等.驻某地海军部队消化性溃疡流行病学浅析[J].解放军预防医学杂志,1995,13(6):462-463.
[12]王晓君.军人消化性溃疡的流行病学特点及防治[J].解放军医学杂志,2006,31(2):206-208.
[13] Kato, Ikuko, Abraham M. Y. Nomura, Grant N. Stemmermann and Po-HuangChyou. A Prospective Study of Gastric and Duodenal Ulcer and Its Relation toSmoking, Alcohol, and Diet[J]. American Journal of Epidemiology.1992,135(5):521-530.
[14] Salih, Barik, M Fatih Abasiyanik, Nizamettin Bayyurt, Ersan Sander. H pyloriinfection and other risk factors associated with peptic ulcers in Turkish patients: Aretrospective study[J]. World J Gastroenterol.2007,13(23):3245-8.
[15] Kenneth Thorsen, Jon Arne S reide, Jan Terje Kval y, Tom Glomsaker, KjetilS reide. World J Gastroenterol.2013,19(3):347–354.
[16] Kurata Ph.D., M.P.H., John H., Nogawa, Aki N. M.S."Meta-analysis of RiskFactors for Peptic Ulcer: Nonsteroidal Antiinflammatory Drugs, Helicobacter pylori,and Smoking"[J]. Journal of Clinical Gastroenterology,1997,24(1):2-17.
[17] Tsu-Hui Shiao, Chia-Jen Liu, Jiing-Chyuan Luo, Kang-Cheng Su, Yuh-Min Chen,Tzeng-Ji Chen, Kun-Ta Chou, Guang-Ming Shiao, Yu-Chin Lee. Sleep Apnea andRisk of Peptic Ulcer Bleeding: A Nationwide Population-based Study[J]. AM J Med.2013,126(3):249-255.
[18] C. Musumba, A. Jorgensen3, L. Sutton, D. Van Eker1, J. Moorcroft, M. Hopkins, D.M. Pritchard, M. Pirmohamed. ALIMENT PHARM THERAP.2012,36(1):48-56.
[19] Hisato Deguchi, Keiji Yasukawa, Toshihide Yamasaki, Fumiya Mito, YuichiKinoshita, Tatsuya Naganuma, Suguru Sato, Mayumi Yamato, Kazuhiro Ichikawa,Kiyoshi Sakai, Hideo Utsumi, Ken-ichi Yamada. Nitroxides prevent exacerbation ofindomethacin-induced gastric damage inadjuvant arthritis rats[J]. FREE RADICALBIO MED.2011(51):1799-1805.
[20] P. Juillerat1, S. Schneeweiss, E. F. Cook, A. N. Ananthakrishnan, H. Mogun, J. R.Korzenik. Drugs that inhibit gastric acid secretion may alter the course ofinflammatory bowel disease[J]. ALIMENT PHARM THERAP.2012,36(3):239-247.
[21] Jia Wu, Song Xu, Yongliang Zhu. Helicobacter pylori CagA: A Critical Destroyer ofthe Gastric Epithelial Barrier[J]. DIGEST DIS SCI. DOI:10.1007/s10620-013-2589-x.
[22] Hobsley M, Tovey F I. Helicobacter pylori: the primary cause of duodenal ulcerationor a secondary infection?[J]. World Journal of Gastroenterology,2001,7(2):149-151.
[23] Genta R M, Kinsey R S, Singhal A, et al. Gastric foveolar metaplasia and gastricheterotopia in the duodenum: no evidence of an etiologic role for Helicobacterpylori[J]. Human pathology.2010,41(11):1593-1600.
[24] Bauer B, Meyer T F. The human gastric pathogen Helicobacter pylori and itsassociation with gastric cancer and ulcer disease[J]. Ulcers,2011, doi:10.1155/2011/340157.
[25] Muraoka S, Miura T. Metabolism of non-steroidal anti-inflammatory drugs byperoxidase: implication for gastrointestinal mucosal lesions][J]. Yakugaku zasshi: JPharmaceutical Society of Japan,2007,127(4):749-756.
[26] Bjarnason I, Scarpignato C, Takeuchi K, et al. Determinants of the short‐termgastric damage caused by NSAIDs in man[J]. Alimentary pharmacology&therapeutics,2007,26(1):95-106.
[27] Lanza FL, Chan FK, Quigley EM, et al. Guidelines for p revention of NSA ID-related ulcer comp lications [J]. Am J Gastroenterol,2009,104:728-738.
[28] Thorsen K, S reide J A, Kval y J T, et al. Epidemiology of perforated peptic ulcer:Age-and gender-adjusted analysis of incidence and mortality[J]. WORLD JGASTROENTERO,2013,19(3):347-354.
[29] Salih B A, Abasiyanik M F, Bayyurt N, et al. H pylori infection and other riskfactors associated with peptic ulcers in Turkish patients: A retrospective study[J].WORLD J GASTROENTERO,2007,13(23):3245-3248.
[30] Sondashi K J, Odimba B F K, Kelly P. A Cross-sectional Study on FactorsAssociated With Perforated Peptic Ulcer Disease in Adults Presenting to UTH,Lusaka[J]. Medical Journal of Zambia,2012,38(2):15-22.
[31] Musumba C. Letter: peptic ulcer bleeding in patients with cirrhosis[J]. ALIMENTPHARM THERAP.2012,36(6):597-598.
[32] Hernández-Díaz S, Martín-Merino E, Rodríguez L A G. Risk of Complications Aftera Peptic Ulcer Diagnosis: Effectiveness of Proton Pump Inhibitors[J]. DIGEST DISSCI,2013:1-10.
[33]陈韶华,厉有名.酒精性胃黏膜损伤的研究进展[J].国际消化病杂志.2006,26(4);249-250.
[34] Linea C, Sinagra E, La Seta F, et al. Acquired double pylorus, due to penetratinggastric ulcer, presenting with melena[J]. World Journal of GastrointestinalEndoscopy,2012,4(3):94-95.
[35]罗燕军,于皆平.胃黏膜血流变化的影响因素[J].世界华人消化杂志.2001,9(6);671-674.
[36] Chen S, Gao H, Wang J, et al. Su1632Evaluation of Prokinetic Drugs on GastricEmptying of Solid in Patients With Postprandial Distress Syndrome[J].Gastroenterology,2012,142(5): S468-S469.
[37] Wu D Y, Guo M, Gao Y S, et al. Clinical effects of psychological intervention anddrug therapy against peptic ulcer[J]. Asian Pacific journal of tropical medicine,2012,5(10):831-833.
[38] Peptic ulcer. A.D.A.M. Medical Encyclopedia. U.S. National Library of Medicine.2011, http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001255/.
[39] Tarnawski A, Ahluwalia A, K Jones M. Gastric Cytoprotection BeyondProstaglandins: Cellular and Molecular Mechanisms of Gastroprotective and UlcerHealing Actions of Antacids[J]. Current Pharmaceutical Design,2013,19(1):126-132.
[40] Davenport H W. The gastric mucosal barrier[J]. Digestion,2009,5(3-4):162-165.
[41][41]房殿春,彭志红.胃黏膜屏障功能研究概况[J].现代消化介入及诊疗,2007,12(1);48-52.
[42] Phillipson M. Acid transport through gastric mucus[J]. UPSALA J MED SCI,2004,109(1):1-24.
[43]王烈泉,耿立梅.消化性溃疡[M].北京中国医药科技出版社.2005;23-24.
[44] Li, WF, Jiang, JG, Chen, J. Chinese medicine and its modernizationdemands[J].ARCHIVES OF MEDICAL RESEARCH,2008,39(2)246-251.
[45] Rohit Chugh, Veena Sangwan, Satish P. Patil, Vikas Dudeja,Rajinder K.Dawra,Sulagna Banerjee,Robert J. Schumacher,Bruce R. Blazar,Gunda I.Georg,Selwyn M. Vickers,Ashok K. Saluja. A Preclinical Evaluation of Minnelideas a Therapeutic Agent Against Pancreatic Cancer[J]. Sci Transl Med,2012,4:156-162.
[46] Song H, Guo T, Zhang R, Zheng C, Ma Y, Li X, Bi K, Tang X.Preparation of thetraditional Chinese medicine compound recipe heart-protecting musk pH-dependentgradient-release pellets[J].Drug Dev Ind Pharm,2002,28(10):1261-73.
[47] L. Wang, Zhou, G.B., Liu, P., Song, J.H., Liang, Y., Yan, X.J., et al., Dissection ofmechanisms of Chinese medicinal prescription Realgar-Indigo naturalis as aneffective treatment for promyelocytic leukemia[J]. Proc. Natl. Acad. Sci. U. S.A.,2008,105:4826-4831.
[48]王四旺,谢艳华,孙纪元.中药现代化与“揭示中药物效成分学”[J].中国医学月刊,2002;1(9):743-745.
[49]王四旺.“中药组分”与“揭示中药物效成分”[J].第四军医大学学报,2008;29(18):2280-2284.
[50]王四旺,谢艳华,曹蔚.揭示中药物效成分研究与方法学[M].军事医学科学出版社,2012.
[51] DiMasi, J.A. et al. The price of innovation: new estimates of drug developmentcosts[J]. J. Health Economics,2003,22,151-185.
[52] Yu, Chien-Yu Chen, Chih-Ho Hsu, Hsin-Yi Chen,Kuei-Jen Lee, Fuu-Jen Tsai,Current developments of computer-aided drug design[J].2010,323(5):243-256.
[53] Wen-TsaiSung,Yu-FengLiu. Energy minimumtheorembasedonAGA,Lyapunovandforcefieldf or CADD techniques[J].2012,36(5):239-246.
[54]陈擎文.《伤寒论》的“方-证要素”对应体系及其神经网络数学模型的构建[D].北京中医药大学,2011.
[55] Hou T, Xu X. A new molecular simulation software package–Peking UniversityDrug Design System (PKUDDS) for structure-based drug design[J]. Journal ofMolecular Graphics and Modelling,2001,19(5):455-465.
[56] Chen C Y C. Chemoinformatics and pharmacoinformatics approach for exploringthe GABA-A agonist from Chinese herb suanzaoren[J]. Journal of the TaiwanInstitute of Chemical Engineers,2009,40(1):36-47.
[57] Chen C Y C. Insights into the suanzaoren mechanism—From constructing the3Dstructure of GABA-A receptor to its binding interaction analysis[J]. Journal of theChinese Institute of Chemical Engineers,2008,39(6):663-671.
[58] Qiao X, Hou T, Zhang W, et al. A3D structure database of components fromChinese traditional medicinal herbs[J]. Journal of chemical information andcomputer sciences,2002,42(3):481-489.
[59] Xu X. New concepts and approaches for drug discovery based on traditionalChinese medicine[J]. Drug Discovery Today: Technologies,2006,3(3):247-253.
[60] Tang Y, Zhu W, Chen K, et al. New technologies in computer-aided drug design:toward target identification and new chemical entity discovery[J]. Drug discoverytoday: technologies,2006,3(3):307-313.
[61] Jorgensen W L. The many roles of computation in drug discovery[J]. Science,2004,303(5665):1813-1818.
[62] Chen C Y C. Virtual screening and drug design for PDE-5receptor from traditionalChinese medicine database[J]. Journal of Biomolecular Structure and Dynamics,2010,27(5):627-640.
[63] Chen C Y C. Virtual screening and drug design for PDE-5receptor from traditionalChinese medicine database[J]. Journal of Biomolecular Structure and Dynamics,2010,27(5):627-640.
[64]缪珠雷,李玉虎,包寅,徐栋梁,张辉,王易.计算机辅助设计抗感染中药复方的实验研究.中草药,2009,40(10):1602-1607.
[65]陈守强.丁书文教授用药规律的计算机辅助分析[D].山东中医药大学,2002.
[66]刘保兴.黄精赞育胶囊优选方改善精子运动能力的初步机理研究[D].北京中医药大学,2005.
[67]张林.计算机辅助古代肝病方剂组方规律的研究及古代肝病方剂数据库初探[D].北京中医药大学,2004.
[68]黄河舟.计算机辅助信息处理技术在药物色谱分析中的应用[D].第二军医大学,2004.
[69]马晓琼.人参化学物质基础分析方法研究[D].中国科学院大脸化学物理研究所,2005.
[70]王毅.现代中药创制设计方法学及关键技术研究[D].浙江大学,2007.
[71]沈杰.药物ADMET理论预测方法开发和靶向雌激素受体的药物设计研究[D].华东理工大学,2011.
[72]徐俊.运用CADD探讨穿心莲内酯衍生物抑制ALP_省略_萄糖苷酶的构效关系及构建其跨膜[D].暨南大学,2010.
[73]龙伟.中药复方黄连解毒汤药效物质基础的计算机虚拟筛选研究[D].中国协和医科大学研究生院,2008.
[74]中华人民共和国药典(第一部,2010版)[M].北京,中国医药科技出版,2010.
[75]郑汉臣,蔡少青.药用植物学与生药学(第4版)[M]..北京,人民卫生出版社.2006;284.
[76]王浴生,邓文龙,薛春.中药药理与应用[M].北京;人民卫生出版社,1998.
[77]张笑恺.元胡止痛片主活性成分分析及其药代动力学研究[D].第四军医大学,2012.
[78] Min Q,Bai Y T,Shu S J,et a1.Protective effect of dl-tetrahydropalmatine on liverinjury induced by carbon tetrachloride in mice[J].China J Chin MaterMed,2006,31(6);483-484.
[79] Lin M T,Chueh F Y,Hsich M T.The hypothermic effects of dl-tetrahydropalmatinein rats [J].Neurosci Lett,2001(315);53-56.
[80] Wai C L,Hui Z,Michael H,el a1.Anxiolytic-like action of orally adm inistereddl-tetrahydropalmatine in elevated plus-maze[J].Prog Neuro-psychopharmacol BiolPsychiat,2003(27);775-779.
[81] Chang C K,Lin M T. dl-Tetrahydropalmatine may act through inhibition ofamygdaloid release of dopamine to inhibit an epileptic attack in rats[J]. NeurosciLett,2001,307,163-166.
[82] LIU Y, WU C, GONG Z. An Experimental Study on the Inhibited Effects ofL-Tetrahydropalmatine on Oxycodone-induced Physical Dependence in Mice andRats[J].Chin J Dr ug Abuse Prey Treat,2005(3);150-152.
[83] Hsieh C L, Liao E T, Chiang S Y, et al. Effect of Rhizoma Corydalis on focalcerebral infarct in ischemia-reperfusion injured rats[J]. Acta Pharmacologica Sinica,2001,22(12):1143-1148.
[84]]Jing T, Kun J, Kunjie L, et al. Determination of Trantinterol Enantiomers in RatLiver S9Fraction by Pre-column Derivatization HPLC[J]. China Pharmacist.2011,3:339-342..
[85]宫照东.四氢巴马汀对雌性大鼠血清中催乳素水平影响的研究[J].中医药学刊,2003,21(5):694-694.
[86] Guo W, Sun J, Jiang L, et al. Imperatorin Attenuates LPS-Induced Inflammation bySuppressing NF-κB and MAPKs Activation in RAW264.7Macrophages[J].Inflammation,2012,35(6):1764-1772.
[87] Ban H S, Lim S S, Suzuki K, et al. Inhibitory effects of furanocoumarins isolatedfrom the roots of Angelica dahurica on prostaglandin E2production[J]. Plantamedica,2003,69(05):408-412.
[88] Hong J J, Shin K H, Lim S S, et al. Lead compounds for anti-inflammatory drugsisolated from the plants of the traditional oriental medicine in Korea[J].Inflammation&Allergy-Drug Targets,2008,7(3):195-202.
[89]嵇杨,曾国前,等.欧芹素乙和异欧芹素乙对小鼠腹腔巨噬细胞体外释放肿瘤坏死因子的一致作用[J].第二军医大学学报,1994,156;511-513.
[90] Márquez N, Sancho R, Ballero M, et al. Imperatorin inhibits T-cell proliferation bytargeting the transcription factor NFAT[J]. Planta medica.2004,70(11):1016-1021.
[91] Sancho R, Márquez N, Gómez-Gonzalo M, et al. Imperatorin inhibits HIV-1replication through an Sp1-dependent pathway[J]. Journal of Biological Chemistry,2004,279(36):37349-37359.
[92] Widelski J, Popova M, Graikou K, et al. Coumarins from Angelica lucidaL.-antibacterial activities[J]. Molecules.2009,14(8):2729-2734.
[93] Patra A K. An Overview of Antimicrobial Properties of Different Classes ofPhytochemicals[M]. Dietary Phytochemicals and Microbes. Springer Netherlands,2012:1-32.
[94] Luszczki J J, Wojda E, Andres-Mach M, et al. Anticonvulsant and acute neurotoxiceffects of imperatorin, osthole and valproate in the maximal electroshock seizureand chimney tests in mice: a comparative study[J]. Epilepsy research,2009,85(2):293-299.
[95] Tzu-Yu Lin, Cheng-Wei Lu, Wei-Jan Huang, Su-Jane Wang. Lin T Y, Lu C W,Huang W J, et al. Osthole or imperatorin‐mediated facilitation of glutamate releaseis associated with a synaptic vesicle mobilization in rat hippocampal glutamatergicnerve endings[J]. Synapse,2010,64(5):390-396.
[96] Li L, HongJun Y, YongQing X, et al. Effect of Chuanxiong Fangfeng Baizhiprescription on isolated rabbit basilar artery[J]. China Journal of Chinese MateriaMedica,2009,34(11):1415-1417.
[97] Luszczki J J, Wojda E, Andres-Mach M, et al. Anticonvulsant and acute neurotoxiceffects of imperatorin, osthole and valproate in the maximal electroshock seizureand chimney tests in mice: a comparative study[J]. Epilepsy research,2009,85(2):293-299.
[98]李铁军,徐添颖,芮耀诚,等.欧芹素乙对大鼠脑缺血再灌注损伤的保护作用[J].第二军医大学学报,2004,25(4):431-433.
[99] Santos A P, Moreno P R H. Pilocarpus spp.: a survey of its chemical constituents andbiological activities[J]. Revista Brasileira de Ciências Farmacêuticas,2004,40(2):116-137.
[100] Irungu B N, Mbabub M J, Kiboi D M, et al. In vivo antimalarial and acute toxicityproperties of hexane and chloroform extracts from Clausena anisata (Willd.)Benth[J]. African Journal of Pharmacology and Therapeutics Vol,2012,1(1):24-29.
[101] Bauer R, Xiao P G. Fructus Cnidii Shechuangzi[M].Chromatographic FingerprintAnalysis of Herbal Medicines. Springer Vienna,2011:499-508.
[102] Tang C H, Yang R S, Chien M Y, et al. Enhancement of bone morphogeneticprotein-2expression and bone formation by coumarin derivatives via p38andERK-dependent pathway in osteoblasts[J]. European journal of pharmacology,2008,579(1-3):40-49.
[103] Nisa F, Hermawan A, Murwanti R, et al. Antiproliferative effect of gynuraprocumbens (lour.) Merr. Leaves etanolic extract on7,12-dimethylbenz (a)antracene induced male rat liver[J]. Advanced Pharmaceutical Bulletin,2012,2:99-106.
[104] Biskup E, Lojkowska E. Evaluation of biological activities of Rhaponticumcarthamoides extracts[J]. J Med Plants Res,2009,3(12):1092-1098.
[105] Ivey F D, Wang L, Demirbas D, et al. Development of a fission yeast-basedhigh-throughput screen to identify chemical regulators of cAMPphosphodiesterases[J]. Journal of biomolecular screening,2008,13(1):62-71.
[106]梁新丽,廖正根,王光发,等.白芷提取物与延胡索总碱配伍对延胡索乙素在大鼠体内药代动力学的影响[J].药学学报,2009；4(6);645-650.
[107]祝婧云,廖正根,陈绪龙,等.元胡白芷有效组分配伍对延胡索乙素小肠吸收的影响[J].江西中医学院学报,2009；21(3);56-59.
[108]金国章.中药延胡索研究中的新发现[M].上海;科学技术出版社.2001;71-1l1.
[109]金国章.胡江元.颅痛定(rotundine)的镇痛作用机制与多巴胺受体.药理学进展[M].北京;科学出版社,1999;64.
[110] Wang C, Li S, Li C, et al. Molecular cloning, expression profile, polymorphism andthe genetic effects of the dopamine D1receptor gene on duck reproductive traits[J].Molecular biology reports,2012,39(9):9239-9246.
[111] Popesku J T, Navarro-Martín L, Trudeau V L. Evidence for alternative splicing of adopamine D2receptor in a teleost[J]. Physiological and Biochemical Zoology,2011,84(2):135-146.
[112] Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamineD3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments ofworking memory, attention set-shifting, and recognition memory in the mouse[J].Psychopharmacology,2013,226(1):91-100.
[113] Seeman P. Historical overview: introduction to the dopamine receptors[M].TheDopamine Receptors. Humana Press,2010:1-21.
[114] Rondou P, Haegeman G, Van Craenenbroeck K. The dopamine D4receptor:biochemical and signalling properties[J]. Cellular and molecular life sciences,2010,67(12):1971-1986.
[115]朱子涛,傅雨,胡国渊,金国章.左旋千金藤啶碱D1激动-D2阻滞作用引起伏核双相放电活动的电生理研究.生理学报,2000,(2):123-130.
[116] Motawi T K, Hamed M A, Hashem R M, et al. Protective and Therapeutic Effects ofArgyreia speciosa against Ethanol-Induced Gastric Ulcer in Rats[J]. Zeitschrift furNaturforschung C-Journal of Biosciences,2012,67(1):47-57.
[117]李和泉,常青,聂桦,等.多巴胺对大鼠胃粘膜表层微循环血液灌注的影响[J].中国医科大学学报,1989,18(3):177-180.
[118] Eliassi A, Aleali F, Ghasemi T. PERIPHERAL DOPAMINE D2‐LIKERECEPTORS HAVE A REGULATORY EFFECT ON CARBACHOL‐,HISTAMINE‐A ND PENTAGASTRIN‐STIMULATED GASTRIC ACIDSECRETION[J]. Clinical and Experimental Pharmacology and Physiology,2008,35(9):1065-1070.
[119] Dawirs R R, Teuchert‐N oodt G. A novel pharmacological concept in an animalmodel of psychosis[J]. Acta Psychiatrica Scandinavica,2001,104(s408):10-17.
[120] Lee T H, Kim K H, Lee S O, et al. Tetrahydroberberine, an isoquinoline alkaloidisolated from corydalis tuber, enhances gastrointestinal motor function[J]. Journal ofPharmacology and Experimental Therapeutics,2011,338(3):917-924.
[121]杨倩,王四旺.延胡索乙素与白芷总香豆素,总挥发油配伍药效学比较研究[J].现代生物医学进展,2009,9(15):2814-2816.
[122]何美蓉,林劲秋,宋于刚.选择性COX-2抑制剂对实验性大鼠胃溃疡愈合及胃酸分泌的影响[J].南方医科大学学报,2007,27(7):91-91.
[123] DiMasi J A, Hansen R W, Grabowski H G. The price of innovation: new estimates ofdrug development costs[J]. Journal of health economics,2003,22(2):151-186.
[124] Xiaofeng Liu, Sisheng Ouyang, Biao Yu, Kai Huang, Yabo Liu, Jiayu Gong, SisuanZheng, Zhihua Li, Honglin Li, Hualiang Jiang. PharmMapper Server: a web serverfor potential drug target identification via pharmacophore mapping approach.Nucleic Acids Research,2010,38, W609-W614.
[125] Zhuo Chen, Xin Wang, Weiping Zhu, Xianwen Cao, Linjiang Tong, Honglin Li, HuaXie, Yufang Xu, Shaoying Tan, Dong Kuang, Jian Ding, and Xuhong Qian.Acenaphtho[1,2-b]pyrrole-Based Selective Fibroblast Growth Factor Receptors1(FGFR1) Inhibitors: Design, Synthesis, and Biological Activity. J. Med. Chem.,2011,54(11),3732-3745.
[126] Liu E S L, Ye Y N, Shin V Y, et al. Interaction of cigarette smoking withcyclooxygenase-2on ulcerative colitis-associated neoplasia in mice[J]. Cancerinvestigation,2007,25(8):750-757.
[127] Zhang W, Zheng S B, Zhuang Y, et al. H+‐K+‐ATPase expression in humanparietal cell and gastric acid secretion in elderly[J]. Journal of Digestive Diseases,2013, DOI:10.1111/1751-2980.12055.
[128] Nguyen N, Kozer-Gorevich N, Gliddon B L, et al. Independent trafficking of theKCNQ1K+channel and H+-K+-ATPase in gastric parietal cells from mice[J].American Journal of Physiology-Gastrointestinal and Liver Physiology,2013,304(2): G157-G166.
[129] Fang H B, Jin L, Zai W C, et al. Synthesis and H+/K+-ATPase Inhibitory Activity of2-Phenyl-6,7-Dihydrobenzofuran-4(5H)-one Oxime Ether Derivatives[J].Advanced Materials Research,2013,634:1192-1195.
[130] Rasheed N, Ahmad A, Singh N, et al. Differential response of A68930and sulpiridein stress-induced gastric ulcers in rats[J]. European journal of pharmacology,2010,643(1):121-128.
[131] Thany S H, Tricoire-Leignel H, Lapied B. Identification of Cholinergic SynapticTransmission in the Insect Nervous System[M].Insect Nicotinic AcetylcholineReceptors. Springer New York,2010:1-10.
[132] Becker D E. Basic and Clinical Pharmacology of Autonomic Drugs[J]. Anesthesiaprogress,2012,59(4):159-169.
[133] Lotti V J, Chang R S L, Kling P J, et al. Evidence that cholecystokinin octapeptide(CCK-8) acts as a potent, full agonist on gastrin receptors for acid secretion in theisolated mouse stomach: lack of antagonism by the specific CCK antagonistasperlicin[J]. Digestion,2009,35(3):170-174.
[134] LI Y, WANG J H, LAO S X, et al. Inhibitory action of dl-tetrahydropalmatine ongastric acid secretion in vitro [J][J]. Chinese Pharmacological Bulletin,1993,(1):44-47.
[135] KUO-CHANG T, BIN H S U. STUDIES ON THE PHARMACOLOGICALACTIONS OF CORYDALIS Ⅶ. INFLUENCE OF CORYDALIS B ON GASTRICSECRETION AND ITS HYPNOTIC ACTION IN DOGS[J]. Acta PharmaceuticaSinica,1962,(3):145-150.
[136] Brzozowski T, Konturek P C, Konturek S J, et al. Effect of local application ofgrowth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1and-2[J]. Digestion,2001,64(1):15-29.
[137]郭宏.多巴胺受体激动剂与多巴胺神经元的生长和发育[D].中国科学院研究生院(上海生命科学研究院),2003.
[138]杨倩,王四旺.延胡索乙素与白芷总香豆素,总挥发油配伍药效学比较研究[J].现代生物医学进展,2009,9(15):2814-2816.
[139] Wang L, Zhou G B, Liu P, et al. Dissection of mechanisms of Chinese medicinalformula Realgar-Indigo naturalis as an effective treatment for promyelocyticleukemia[J]. Proceedings of the National Academy of Sciences,2008,105(12):4826-4831.
[140] Anonymous. The Inner Canon of Emperor Huang[M]. Chinese Medical AncientBooks Publishing House,Beijing,2003.
[141] López-Armada M J, Valcárcel-Ares M N, Riveiro-Naveira R R, et al. Nitric Oxideand the Respiratory Chain in Synovial Cells and Chondrocytes[M].Studies onArthritis and Joint Disorders. Springer New York,2013:49-66.
[142] Luiz-Ferreira A, Almeida A C A, Cola M, et al. Mechanisms of the gastricantiulcerogenic activity of Anacardium humile St. Hil on ethanol-induced acutegastric mucosal injury in rats[J]. Molecules,2010,15(10):7153-7166.
[143] Yi L, Lingshan G, Cui Y, et al. A preliminary study on protective effect ofL-citrulline against ischemia-reperfusion induced gastric mucosal lesions in rat[J].Indian journal of pharmacology,2012,44(1):31-35.
[144] Yu H, Sato E F, Minamiyama Y, et al. Effect of nitric oxide on stress-induced gastricmucosal injury in the rat[J]. Digestion,2009,58(4):311-318.
[145] Qiu B S, Pfeiffer C J, Cho C H. Effects of Chronic Nitric Oxide Synthase Inhibitionin Cold-Restraint and Ethanol-lnduced Gastric Mucosal Damage in Rats[J].Digestion,2009,57(1):60-66.
[146] Szlachcic A, Krzysiek-Maczka G, Pajdo R, et al. The impact of asymmetricdimethylarginine (ADAMA), the endogenous nitric oxide (NO) synthase inhibitor,to the pathogenesis of gastric mucosal damage[J]. Current Pharmaceutical Design,2013,19(1):90-97.
[147] Konturek S K, Ch K P. Role of nitric oxide in the digestive system[J]. Digestion,2009,56(1):1-13.
[148] Zhang G F, Zhang M A, Chen Y R, et al. The roles of endothelin and nitric oxide ingastric mucosa injuries in rats with endotoxemia[J]. World Chin J Digestol,2000,8:24-28.
[149] Lundberg J O, Weitzberg E. Biology of nitrogen oxides in the gastrointestinaltract[J]. Gut,2013,62(4):616-629.
[150]郭津生,古永亮,王吉耀,等.结构型与诱生型一氧化氮合酶在大鼠胃溃疡模型中的表达和活性变化[J].世界华人消化杂志,2001,9(3):288-292.
[151] Brzozowski T, Konturek S J, Drozdowicz D, et al. Healing of chronic gastriculcerations by L-arginine[J]. Digestion,2009,56(6):463-471.
[152] von der Leyen H E, Mügge A, Hanefeld C, et al. A prospective, single-blind,multicenter, dose escalation study of intracoronary iNOS lipoplex (CAR-MP583)gene therapy for the prevention of restenosis in patients with de novo or restenoticcoronary artery lesion (REGENT I Extension)[J]. Human gene therapy,2010,22(8):951-958.
[153] Perron N, Tremblay E, Ferretti E, et al. Deleterious effects of indomethacin in themid-gestation human intestine[J]. Genomics,2013,101(3):171-177.
[154] Choi S C, Oh H M, Park J S, et al. Soluble Factor from Murine Bladder Tumor-2Cell Elevates Nitric Oxide Production in Macrophages and Enhances theTaxol-Mediated Macrophage Cytotoxicity on Tumor Cells: ORIGINAL ARTICLE[J]. Cancer investigation,2003,21(5):708-719.
[155] Sosroseno W, Bird P S, Seymour G J. Effect of exogenous nitric oxide on murineimmune response induced by Aggregatibacter actinomycetemcomitanslipopolysaccharide[J]. Journal of periodontal research,2009,44(4):529-536.
[156] Polli-Lopes A C, Estofolete C F, Oliani S M, et al. Myenteric denervation in gastriccarcinogenesis: differential modulation of nitric oxide and annexin-A1[J].International journal of clinical and experimental pathology,2013,6(1):13-23.
[157] Xaus J, Comalada M, Valledor A F, et al. LPS induces apoptosis in macrophagesmostly through the autocrine production of TNF-α[J]. Blood,2000,95(12):3823-3831.
[158] McKinney L C, Aquilla E M, Coffin D, et al. Ionizing Radiation Potentiates theInduction of Nitric Oxide Synthase by Interferon‐γ and/or Lipopolysaccharide inMurine Macrophage Cell Lines: Role of Tumor Necrosis Factor‐α [J]. Annals of theNew York Academy of Sciences,2000,899(1):61-68.
[159] Diamantopoulos A P, Hetland H, Hansen A E, et al. Severe deterioration of newlydiagnosed Takayasu arteritis in a patient re-treated with interferon beta-1α forconcomitant longstanding multiple sclerosis[J]. Modern Rheumatology,2012,22(3):474-478.
[160] Ropert C, Almeida I C, Closel M, et al. Requirement of mitogen-activated proteinkinases and IκB phosphorylation for induction of proinflammatory cytokinessynthesis by macrophages indicates functional similarity of receptors triggered byglycosylphosphatidylinositol anchors from parasitic protozoa and bacteriallipopolysaccharide[J]. The Journal of Immunology,2001,166(5):3423-3431.
[161] Li W, Lin J, Adams G L, et al. Expression of inducible nitric oxide synthase (iNOS)in middle ear epithelial cells by IL-1β and TNF-α[J]. International journal ofpediatric otorhinolaryngology,2000,55(2):91-98.
[162] Chairmandurai A R, Kanappa S V, Vadrevu K M, et al. Recombinant HumanEpidermal Growth Factor Alleviates Gastric Antral Ulcer Induced by Naproxen: ANon-steroidal Anti Inflammatory Drug[J]. Gastroenterology Research,2010,3(3):125-133.
[163] Surh Y J, Kundu J K, Li M H, et al. Role of Nrf2-mediated heme oxygenase-1upregulation in adaptive survival response to nitrosative stress[J]. Archives ofpharmacal research,2009,32(8):1163-1176.
[164] Jayakumar A R, Tong X Y, Ospel J, et al. Role of cerebral endothelial cells in theastrocyte swelling and brain edema associated with acute hepatic encephalopathy[J].Neuroscience,2012,218(30):305-316.
[165] Ryter S W, Otterbein L E, Morse D, et al. Heme oxygenase/carbon monoxidesignaling path-ways: Regulation and functional significance[M].Oxygen/NitrogenRadicals: Cell Injury and Disease. Springer US,2002:249-263.
[166] Kitamura Y, Furukawa M, Matsuoka Y, et al. In vitro and in vivo induction of hemeoxygenase‐1in rat glial cells: Possible involvement of nitric oxide production frominducible nitric oxide synthase[J]. Glia,1998,22(2):138-148.
[167] Motterlini R, Foresti R, Bassi R, et al. Endothelial Heme Oxygenase-1Induction byHypoxia MODULATION BY INDUCIBLE NITRIC-OXIDE SYNTHASEANDS-NITROSOTHIOLS[J]. Journal of Biological Chemistry,2000,275(18):13613-13620.
[168] Ishikawa K, Navab M, Lusis A J. Vasculitis, Atherosclerosis, and Altered HDLComposition in Heme-Oxygenase-1-Knockout Mice[J]. International journal ofhypertension,2012,2012:doi:10.1155/2012/948203.
[169] Willis D, Moore A R, Willoughby D A. Heme oxygenase isoform expression incellular and antibody‐mediated models of acute inflammation in the rat[J]. TheJournal of pathology,2000,190(5):627-634.
[170] Haschemi A, Chin B Y, Jeitler M, et al. Carbon monoxide induced PPARγSUMOylation and UCP2block inflammatory gene expression in macrophages[J].PloS one,2011,6(10): e26376.doi:10.1371/journal.pone.0026376.
[171] Yoshimura T, Sugata H. Alcohol scavenges nitric oxide in gastric lumen[J]. NitricOxide,2002,6(3):347-352.
[172] Sakai H, Ohira Y, Tanaka A, Suzuki T, Ikari A, Morii M, Takeguchi N. Inhibition ofsmall-conductance Cl-channels by the interleukin-1beta-stimulated production ofsuperoxide in rabbit gastric parietal cells[J]. J Physiol,2003,551:207-217.
[173] Konturek P C, Kania J, Hahn E G, et al. Ascorbic acid attenuates aspirin-inducedgastric damage: role of inducible nitric oxide synthase[J]. Journal of physiology andpharmacology,2006,57:125.
[174]夏敏,陶嘉泳.乙醇对小鼠胃粘膜的损伤机制[J].新消化病学杂志,1997,5(4):211-212.
[175] Tepperman B L, Chang Q, Soper B D. The involvement of protein kinase C in nitricoxide‐induced damage to rat isolated colonic mucosal cells[J]. British journal ofpharmacology,1999,128(6):1268-1274.
[176] Kato S, Ohkawa F, Ito Y, et al. Role of endothelial nitric oxide synthase inaggravation of indomethacin-induced gastric damage in adjuvant arthritic rats[J]. JPhysiol Pharmacol,2009,60(4):147-155.
[177] Sultana R, Butterfield D A. Brain Protein Oxidation and Modification for Good orfor Bad in Alzheimer’s Disease[M].Neurochemical Mechanisms in Disease.Springer New York,2011:585-605.
[178] Zhi Q, Wang S, Chai M, et al. Transgenic mini-tomato and protection againstalcohol-induced gastric injury[J]. Journal of Genetics and Genomics,2007,34(8):756-763.
[179] Banan A, Zhang L, Fields J Z, et al. PKC-ζ prevents oxidant-induced iNOSupregulation and protects the microtubules and gut barrier integrity[J]. AmericanJournal of Physiology-Gastrointestinal and Liver Physiology,2002,283(4):G909-G922.
[180] Banan A, Zhang L J, Shaikh M, et al. Key role of PLC-γ in EGF protection ofepithelial barrier against iNOS upregulation and F-actin nitration and disassembly[J].American Journal of Physiology-Cell Physiology,2003,285(4): C977-C993.
[181] Puri S, Ray A, Chakravarti A K, et al. A differential dopamine receptor involvementduring stress ulcer formation in rats[J]. Pharmacology Biochemistry and Behavior,1994,47(3):749-752.
[182] Schepp W, Schmidtler J, Tatge C, et al. Effect of substance P and neurokinin A on ratparietal cell function[J]. American Journal of Physiology-Gastrointestinal and LiverPhysiology,1990,259(4): G646-G654.
[183] Yokotani K, Fujiwara M. Effects of substance P on cholinergically stimulated gastricacid secretion and mucosal blood flow in rats[J]. Journal of Pharmacology andExperimental Therapeutics,1985,232(3):826-830.
[184] Perelson A S, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infectedcompartments during combination therapy[J].1997.
[185] Chabner B A, Roberts T G. Chemotherapy and the war on cancer[J]. Nature ReviewsCancer,2005,5(1):65-72.
[186]王光发,廖正根,梁新丽,等. HPLC法同时测定元胡止痛片中3种活性成分的含量[J].中国药房,2009,20(9):672-674.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |